Artemisinin
12 benefits mapped to clinical evidence across supplements.
Dose per serving from products
40 products in our catalogue print how much Artemisinin a serving holds.
Most common: 100 mg to 250 mg, 53% of 40 products.
| Dose per serving | Products |
|---|---|
| 10 mg to 25 mg | 3 |
| 25 mg to 50 mg | 1 |
| 50 mg to 100 mg | 9 |
| 100 mg to 250 mg | 21 |
| 250 mg to 500 mg | 2 |
| 500 mg to 1 g | 4 |
Dose per serving from research
40 study groups in 24 studies say how much Artemisinin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 33% of 40 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg to 25 mg | 3 |
| 25 mg to 50 mg | 13 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 8 |
| 250 mg to 500 mg | 12 |
| over 500 mg | 1 |
Commonly used together
34 of 63 study groups took Artemisinin with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| piperaquine | 10 |
| amodiaquine | 5 |
| lumefantrine | 3 |
| naphthoquine | 3 |
Benefit Evidence
Efficacy: +95% cure
PK/safety: exposure changes
Transmission: -50% gametocytes
HIV/CD4: +2.24 risk
Less malaria/anemia: −69%
Immune cells/cytokines: faster clearance
Clearance faster; cognition unchanged
Negatives improved; cognition unchanged
Efficacy: +95% cure
PK/safety: exposure changes
Transmission: -50% gametocytes
HIV/CD4: +2.24 risk
Less malaria/anemia: −69%
Immune cells/cytokines: faster clearance
Research sources
Antimicrobial (645)
- Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria
PubMed ID: 19690618
CDA had somewhat lower cure rates and safety issues; artesunate-containing arms still show antiparasitic activity but with safety caveats.
- [Short course schemes for vivax malaria treatment]
PubMed ID: 12806460
Artemisinin cleared P. vivax more rapidly than chloroquine — antiparasitic support for vivax species.
- A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso
PubMed ID: 15078261
Randomized pediatric trial: artesunate-containing regimens cleared fever/parasites faster than AQ alone — direct infection benefit.
- Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria
PubMed ID: 15482401
Adding artesunate markedly lowered treatment failure (parasite persistence) vs AQ alone.
- Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand
PubMed ID: 15499533
DHA‑piperaquine highly effective and safe in multidrug‑resistant falciparum — strong antimalarial protection.
- Randomized control trial of quinine and artesunate in complicated malaria
PubMed ID: 15107507
Artesunate superior to quinine in severe pediatric malaria for clinical and parasitological recovery — high antimalarial protection.
- Efficacy of mefloquine and mefloquine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon region of Bolivia
PubMed ID: 15040558
MQ+AS reduced parasite densities faster and lowered gametocyte prevalence.
- Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial
PubMed ID: 15567011
Artesunate-containing combos greatly reduced treatment failures vs CQ+SP — strong protection evidence.
- Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial
PubMed ID: 14723988
Vietnam trials: DHA combos effective for multidrug-resistant infections — strong protection.
- Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar
PubMed ID: 15548314
Myanmar RCTs: mefloquine/artesunate low failure rates compared to failing drugs — direct protection.
- CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam
PubMed ID: 15040557
DHA/piperaquine eliminated parasites effectively—direct antiparasitic finding.
- Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study
PubMed ID: 15145633
Rectal artesunate rapidly reduced parasite density in children/adults—strong antiparasitic action.
- Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria
PubMed ID: 15047537
Artesunate shortened parasite clearance and reduced gametocyte carriage vs quinine—direct clinical antimalarial benefit.
- A randomized, comparative study of two regimens of beta-artemether for the treatment of uncomplicated, Plasmodium falciparum malaria, in northern Ghana
PubMed ID: 15257791
Beta-artemether regimens were safe and highly effective with high cure rates—direct antimalarial evidence.
- Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens
PubMed ID: 15024929
Three-day artesunate-mefloquine regimens reduced recrudescence and post-treatment anaemia—strong antimalarial clinical trial.
- Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand
PubMed ID: 15689068
Five-day artesunate rapidly cleared P. vivax fever/parasites with 100% 14-day cure—clear antimalarial efficacy.
- Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria
PubMed ID: 15642961
Dose-related blood levels with arteether and modest parasite/febrile responses—antimalarial but limited efficacy.
- Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes
PubMed ID: 14728607
Adding artesunate to chloroquine sharply reduced gametocytes and transmission—strong antimalarial/transmission effect.
- Artesunate with mefloquine at various intervals for non-severe Plasmodium falciparum malaria
PubMed ID: 15306704
Artesunate-mefloquine gave good initial parasite clearance though recurrence occurred—antiparasitic evidence for early effect.
- Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda
PubMed ID: 16033307
Artemisinin combos cleared parasites fastest and reduced recrudescence—strong antiparasitic support.
- A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria
PubMed ID: 15941413
SP+AS markedly improved ACPR and cleared parasites faster—clear antiparasitic outcome.
- Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial
PubMed ID: 15909266
Artesunate+clindamycin cleared fever/parasites faster in children though 28-day cure similar—antimalarial effect on speed.
- Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a preliminary study
PubMed ID: 15828586
DHA produced faster parasitological recovery in adults—demonstrates antiparasitic action.
- Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola
PubMed ID: 15876443
Extremely low day-28 failure rates for artemisinin combos in children—strong antiparasitic evidence.
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
PubMed ID: 16125588
Intravenous artesunate rapidly cleared parasites in severe malaria and reduced mortality—definitive antiparasitic effect.
- An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria
PubMed ID: 16438129
DHA-piperaquine and artesunate-mefloquine both achieved high parasite cure rates—antiparasitic equivalence.
- A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy
PubMed ID: 16088834
Artesunate-based combo cleared infections faster in pregnant women—antiparasitic benefit.
- Efficacies of mefloquine alone and of artesunate followed by mefloquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan
PubMed ID: 15814029
Combination reduced gametocytemia to zero post-treatment—important antiparasitic/transmission effect.
- A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria
PubMed ID: 16028147
Excellent long-term PCR-adjusted cure rates with DP regimens—strong antiparasitic support.
- An open, randomized trial of three-day treatment with artesunate combined with a standard dose of mefloquine divided over either two or three days, for acute, uncomplicated falciparum malaria
PubMed ID: 16124422
High cure and rapid parasite clearance with artesunate+mefloquine—clear antiparasitic evidence.
- Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan
PubMed ID: 15941414
Artesunate combinations markedly increased malaria cure rates and reduced gametocyte carriage vs comparator — strong antiparasitic effect.
- Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations
PubMed ID: 15869770
Three-day artesunate combinations produced >90% cures and rapid clearance in children — strong antimalarial infection control.
- Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana
PubMed ID: 16054584
Artemisinin-based combinations gave near-complete parasitological cures and faster clearance in children — very strong antiparasitic evidence.
- Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial
PubMed ID: 15705690
Rectal artemether showed similar or faster parasite clearance compared with quinine in cerebral malaria — effective antiparasitic action.
- Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia
PubMed ID: 15679556
SP+artesunate cured most children when dosing was supervised; effectiveness fell with poor adherence — strong drug effect on infection modified by adherence.
- Efficacy and tolerability of artesunate plus sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine alone for the treatment of uncomplicated Plasmodium falciparum malaria in Peru
PubMed ID: 15891131
SP+artesunate shortened fever and parasite clearance and reduced gametocytemia vs SP alone — direct infection control benefit.
- A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China
PubMed ID: 16112071
Repeated artemether dramatically reduced Schistosoma japonicum incidence and egg counts — very strong antiparasitic evidence.
- Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children
PubMed ID: 16262741
AS+AQ cleared parasitemia faster and cured more children with greatly reduced gametocyte carriage — robust antiparasitic outcome.
- A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan
PubMed ID: 16004704
Artesunate+SP cleared fever and parasites faster and prevented gametocyte carriage vs SP — strong anti-infective evidence.
- Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes
PubMed ID: 17002724
AS+AQ showed fewer recurrences and lower recrudescence than AS+SP — antiparasitic advantage linked to partner-drug resistance patterns.
- Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison
PubMed ID: 16798391
DHA-piperaquine and artesunate-mefloquine produced very low failure rates in a large trial — strong anti-infective efficacy.
- Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial
PubMed ID: 16503464
Seasonal artesunate+SP IPT produced an ~86% reduction in clinical malaria episodes — robust preventive antiparasitic evidence.
- Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum
PubMed ID: 16544256
ACTs reduced gametocyte levels and mosquito infection moderately, indicating antiparasitic/transmission effects though residual submicroscopic gametocytes persisted.
- An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos)
PubMed ID: 16903879
Both artesunate-containing regimens cured almost all patients; strong anti-infective efficacy.
- Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea
PubMed ID: 16495259
Artesunate suppositories produced faster parasite clearance and higher early drug levels in severe pediatric malaria — strong antiparasitic effect.
- Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia
PubMed ID: 17105658
CQ+SP improved cure and primaquine rapidly cleared gametocytes — relevant to antiparasitic strategies though not focused on artemisinin.
- Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children
PubMed ID: 16766006
DHA-piperaquine produced higher cure and faster clearance than the comparator — strong antiparasitic efficacy in children.
- An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand
PubMed ID: 17054744
Co-formulated mefloquine-artesunate was as effective as separate tablets with less early vomiting — effective anti-infective regimen with improved tolerability.
- Efficacy and safety of beta-arteether and alpha/beta-arteether for treatment of acute Plasmodium falciparum malaria
PubMed ID: 16837720
Arteether formulations were safe and effective in treating acute falciparum malaria — clear antiparasitic evidence.
- Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar
PubMed ID: 17519010
Pediatric trial where artesunate-containing regimen produced much higher cure rates and faster parasite clearance — strong antiparasitic evidence.
- Artesunate, artemether or quinine in severe Plasmodium falciparum malaria?
PubMed ID: 17402835
Multicentre RCT demonstrating artesunate reduced mortality in severe falciparum malaria, direct evidence of potent antiparasitic clinical benefit.
- Effect of artesunate plus sulfadoxine-pyrimethamine on haematological recovery and anaemia, in Kenyan children with uncomplicated, Plasmodium falciparum malaria
PubMed ID: 17524243
Although no Hb benefit, trial context (malaria treatment with artesunate) is directly related to antiparasitic therapy.
- A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women
PubMed ID: 18000538
Artesunate+SP in pregnancy greatly sped parasite clearance and reduced recrudescence — antiparasitic effect in pregnant population.
- A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan
PubMed ID: 18074034
AS+SP cleared most submicroscopic infections in asymptomatic carriers — antiparasitic help for transmission reservoirs.
- A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru
PubMed ID: 17971864
DHA–piperaquine cured malaria and cleared parasites faster at 24 h — direct antiparasitic demonstration.
- Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria
PubMed ID: 17967917
Melanesian pediatric study: DHA–piperaquine yielded very high cure rates (antiparasitic support).
- Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia
PubMed ID: 17328806
AQ+AS reduced gametocyte emergence and maintained cure — antiparasitic and transmission-limiting benefit.
- Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria
PubMed ID: 17846129
PK–outcome link shows importance of partner-drug concentrations (piperaquine) for preventing recurrence — relevant to antiparasitic durability.
- Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate
PubMed ID: 17925871
Primaquine added to SP+AS cleared submicroscopic gametocytes nearly completely (strong antiparasitic/transmission-blocking effect).
- Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children
PubMed ID: 17325222
Artesunate regimens cleared parasites faster and reduced gametocyte carriage in Nigerian children — robust antiparasitic support.
- Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa
PubMed ID: 18154655
Community-based randomized trial: adding artesunate to SP dramatically lowered treatment failure and sped parasite/fever clearance.
- Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria
PubMed ID: 17366451
DHA–piperaquine produced far fewer recurrent infections than artesunate–amodiaquine — strong antiparasitic/recurrence-reduction evidence.
- A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia
PubMed ID: 17300633
DHA–piperaquine matched cure rates of mefloquine–artesunate with better tolerability — supports antiparasitic efficacy.
- Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria
PubMed ID: 17469728
Rectal artesunate followed by mefloquine was safe and effective — antiparasitic application in pediatric care.
- Dihydroartemisinin suppository in moderately severe malaria: comparative efficacy of dihydroartemisinin suppository versus intramuscular artemeter followed by oral sulfadoxine-pyrimethamine in the management of moderately severe malaria in Nigerian children
PubMed ID: 17255220
Rectal/intramuscular artemisinins effective in children — supports antiparasitic formulations for severe/moderate disease.
- Clinical efficacy of high dose monotherapy of oral dihydroartemisinin in uncomplicated falciparum malaria in viet nam
PubMed ID: 17642523
High-dose DHA cleared parasites quickly but had higher relapse vs combination, showing strong initial antiparasitic activity but highlighting need for partner drug.
- Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan
PubMed ID: 17707447
SP+AS was as effective as chloroquine for P. vivax and resulted in fewer recurrences — antiparasitic evidence for vivax treatment.
- Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré
PubMed ID: 17477865
High efficacy of artesunate combinations (very low 28-day failure) — strong antiparasitic support.
- Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate plus sulfamethoxypyrazine/pyrimethamine
PubMed ID: 17978058
Artesunate+SP and artesunate+SMP effective in children — antiparasitic efficacy in field settings.
- Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso
PubMed ID: 18286187
MB+AS arm had fastest parasite clearance in trial — antiparasitic synergy observed.
- Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria
PubMed ID: 18838149
Praziquantel+artesunate produced substantially higher cure rates for urinary schistosomiasis versus single agents — direct antiparasitic evidence.
- Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial
PubMed ID: 19098989
Large randomized trial: monthly AS+AQ IPTc reduced clinical malaria incidence by ~69% and protected against anaemia.
- Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
PubMed ID: 19059639
Community RCT: pre‑referral rectal artesunate halved death or permanent disability in patients delayed in reaching care — strong antimalarial clinical benefit.
- Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand
PubMed ID: 18180343
Piperaquine PK differences by age indicate possible need for dose adjustments to maintain post‑treatment prophylaxis.
- Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand
PubMed ID: 18567436
Artequick (artemisinin–piperaquine±primaquine) achieved similarly high cure rates to standard therapy in uncomplicated falciparum malaria.
- A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam
PubMed ID: 18337331
In human fascioliasis artesunate relieved abdominal pain faster though had lower 3‑month cure than triclabendazole — clear antiparasitic activity but inferior cure.
- Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria
PubMed ID: 18320064
Adding artesunate markedly reduced PC90 and parasite viability — clear antimalarial pharmacodynamic benefit.
- Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children
PubMed ID: 18574653
Artesunate‑containing regimens in Nigerian children produced rapid parasite clearance and reduced gametocyte carriage.
- [Artesunate in interrupting the transmission of Plasmodium falciparum]
PubMed ID: 19157297
Rapid gametocyte clearance and elimination of mosquito infectivity after artesunate (important for malaria control/protection).
- Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria
PubMed ID: 18343702
A 24‑hour three‑pill artesunate regimen cured nearly all uncomplicated falciparum malaria cases — antiparasitic efficacy.
- High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda
PubMed ID: 18444813
Artesunate–amodiaquine effective in Ugandan children, but frequent/severe neutropenia occurred in HIV‑infected kids — efficacy with safety caveat.
- A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria
PubMed ID: 19568711
Piperaquine–artemisinin regimens gave 100% 28‑day cure in uncomplicated falciparum malaria.
- Artemisinin resistance in Plasmodium falciparum malaria
PubMed ID: 19641202
Demonstrated markedly slower parasite clearance in western Cambodia consistent with emerging artemisinin resistance (important for antimalarial protection concerns).
- Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania
PubMed ID: 19352498
Pregnant women trial: AQ+AS showed lower parasitological failure and gametocyte carriage vs older regimens — robust antimalarial effect.
- Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children
PubMed ID: 19784374
IPTc trial in Senegal including a DHA arm showed protective effect but interpretation limited by artemisinin short half‑life.
- Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial
PubMed ID: 19558654
Adding artesunate to SP produced faster parasite clearance and higher cure rates for uncomplicated falciparum malaria — strong infection control evidence.
- Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
PubMed ID: 19698172
Large pooled individual‑patient analysis: AS&AQ shows high PCR‑adjusted efficacy (~94%) and rapid parasite clearance versus non‑ACTs.
- Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial
PubMed ID: 19415120
Adding methylene blue to artesunate markedly reduced gametocytes in children, strongly lowering transmission potential (antiparasitic/gametocytocidal effect).
- Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria
PubMed ID: 19505304
Fixed‑dose artesunate–amodiaquine non‑inferior to standard ACT with high Day28 PCR‑corrected ACPR — high protection evidence.
- Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria
PubMed ID: 19996424
Phase III trial: adding artesunate improved cure vs comparator but caused hemolysis in G6PD‑deficient patients — demonstrates infection efficacy but with important safety caveat.
- Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali
PubMed ID: 19497079
Monthly artesunate‑containing IPT in schoolchildren strongly reduced clinical malaria incidence and asymptomatic parasitaemia.
- Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali
PubMed ID: 19245687
In‑vivo plus molecular surveillance: partner drug choice affects cure; artemisinin combinations superior to older regimens in clearance.
- Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy
PubMed ID: 19671190
Single‑dose artemisinin‑naphthoquine produced faster clearance and fewer gametocytes vs CQ+SP — clear antimalarial efficacy.
- Population pharmacokinetics of artesunate and amodiaquine in African children
PubMed ID: 19691851
Pediatric PK/efficacy study showing similar exposures for fixed‑dose artesunate–amodiaquine with links between partner‑drug levels and recurrence risk (relevance to infection control).
- Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya
PubMed ID: 19194499
ACTs including artesunate greatly reduced gametocyte AUC and mosquito infections — antiparasitic/transmission impact.
- The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
PubMed ID: 19291301
Pediatric fixed‑dose AS‑AQ: high PCR‑corrected cure and rapid parasite clearance—evidence of strong antiparasitic activity in children.
- Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali
PubMed ID: 19128455
Malian pediatric trial: artemisinin combinations cleared parasites fastest with high PCR‑corrected cure (>95%).
- Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications
PubMed ID: 19733875
Field trial compared a traditional decoction to artesunate‑amodiaquine; ACT remained an effective comparator for presumed malaria.
- Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa
PubMed ID: 19257898
Adding artesunate to SP reduced day‑90 clinical failure from ≈41% to 2.7% — extremely strong evidence for antimalarial protection.
- Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam
PubMed ID: 19320869
Vietnam trial: artesunate‑amodiaquine and dihydroartemisinin‑piperaquine produced near‑complete cures through 42 days.
- Therapeutic efficacy and effects of artesunate-mefloquine and mefloquine alone on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria
PubMed ID: 19996425
Large comparative pediatric study of artesunate‑mefloquine vs mefloquine alone assessed cure and anemia — direct, though abstract lacked numeric details.
- [Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development]
PubMed ID: 20128355
Artesunate–mefloquine cured all uncomplicated falciparum cases; adding primaquine sped gametocyte clearance — strong infection control data.
- Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon
PubMed ID: 20170477
Multi‑site Cameroonian program: artesunate‑based combinations produced high cure rates and rapid parasite clearance across sites.
- Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia
PubMed ID: 21028985
Clinical trial documenting emergence of artemisinin-resistant P. falciparum—important infection-relevant evidence though negative for efficacy.
- Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial
PubMed ID: 20368815
Large infant IPTi trial: artesunate-containing long-acting regimens reduced clinical malaria episodes and high-density parasitaemia—protective antimalarial effect.
- Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria
PubMed ID: 20398339
Randomized trial in adults with severe malaria: artesunate cleared parasites faster and trended to lower mortality vs artemether—clear antimalarial superiority.
- A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos
PubMed ID: 21118925
Phase III trial: dihydroartemisinin–piperaquine highly effective and non-inferior to artesunate–mefloquine for uncomplicated falciparum malaria with high cure rates.
- An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia
PubMed ID: 20689583
Large Asia multicenter RCT: DHA–piperaquine non-inferior to artesunate–mefloquine with high PCR-corrected cure rates—strong antimalarial evidence.
- Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial
PubMed ID: 20687837
Phase II trioxolane showing faster clearance at higher doses (repeat entry emphasizes antimalarial relevance).
- Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali
PubMed ID: 21092137
Mali study: ACTs cleared parasites rapidly and produced high 28‑day cure rates irrespective of G6PD genotype—supports antimalarial use across genotypes.
- Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial
PubMed ID: 20832366
Myanmar trial: five ACT regimens effective; primaquine added to ACTs reduced gametocyte carriage ~12-fold, enhancing transmission-blocking antimalarial strategy.
- Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
PubMed ID: 20409302
DP cleared P. vivax faster and reduced recurrences through 56 days versus chloroquine—good antimalarial protection for vivax.
- A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children
PubMed ID: 20065010
Pediatric trial: artesunate+mefloquine and artemether+lumefantrine cured most malaria cases by day 28—clinically meaningful infection control.
- An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixed dose over 48 hours)
PubMed ID: 21194422
Nigerian children: two artesunate-based fixed combinations produced high day-28 cure rates—evidence of anti-infective efficacy.
- Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children
PubMed ID: 20808923
Monthly seasonal AS+AQ IPTc reduced malaria incidence by ~69% — strong protective efficacy.
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
PubMed ID: 21062666
Very large multicentre RCT: parenteral artesunate reduced mortality vs quinine in children with severe falciparum malaria—strongest clinical evidence of antimalarial protection.
- Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
PubMed ID: 21827706
High parasite-clearance and cure rates with artemisinin combos demonstrate strong antiparasitic action.
- Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial
PubMed ID: 21603629
Dose–response trial in an area with delayed clearance showed limited benefit from increased artesunate dose but directly assessed antimalarial efficacy & safety.
- Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial
PubMed ID: 21267072
Rapid clearance of P. vivax and high cure rates with pyronaridine–artesunate show antiparasitic efficacy.
- Effects of lime juice on malaria parasite clearance
PubMed ID: 21413089
Adjunctive lime juice appeared to speed parasite reduction—preliminary antiparasitic adjunct evidence.
- Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial
PubMed ID: 22002979
DHP cleared vivax parasites faster and reduced relapses—clear antiparasitic benefit.
- Efficacy of chloroquine and sulphadoxine-pyrimethamine either alone or in combination before introduction of ACT as first-line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India
PubMed ID: 21564429
Study demonstrating chloroquine failure before ACT rollout underscores the comparative benefit of artemisinin-containing regimens for treating infections.
- Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea
PubMed ID: 21379417
Large pediatric trial showing ACT regimens clinically effective—strong evidence for infection treatment.
- The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam
PubMed ID: 22741618
High cure rates (~98%) with both artemisinin combos — strong antimalarial efficacy.
- Current status of artemisinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in Bangladesh
PubMed ID: 23272227
Artesunate monotherapy produced rapid parasite clearance and high cure rates—direct antiparasitic evidence.
- The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial
PubMed ID: 23175563
Primaquine reduced gametocyte carriage when added to DHP, lowering transmission and supporting antimalarial control.
- Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria
PubMed ID: 22252804
Monthly dihydroartemisinin–piperaquine gave ~98% prevention of malaria episodes — very strong infection-prevention evidence.
- Pyronaridine-artesunate versus mefloquine plus artesunate for malaria
PubMed ID: 22475593
Pyronaridine–artesunate shown noninferior with high ACPR and parasite-clearance data—antiparasitic support.
- Open-label trial of three dosage regimens of fixed-dose combination of artemisinin and naphthoquine for treating uncomplicated falciparum malaria in Calabar, Nigeria
PubMed ID: 23232095
Artemisinin–naphthoquine regimens achieved good 28-day cure rates indicating antiparasitic activity (PCR not done).
- Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia
PubMed ID: 22554203
Both artemisinin–naphthoquine and DHP gave high PCR-corrected ACPR—evidence of antiparasitic effect.
- Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India
PubMed ID: 22818552
DP vs artesunate–mefloquine showed fewer new infections over 63 days with DP—evidence of longer protection from reinfection.
- Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia
PubMed ID: 23254437
Primaquine plus blood schizonticide markedly reduced relapses, demonstrating strong antiparasitic radical cure when combined with artemisinin-class therapy.
- Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial
PubMed ID: 23234606
Artesunate–mefloquine matched artemether–lumefantrine in high cure rates—antiparasitic support.
- Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India
PubMed ID: 22458860
Fixed-dose ASAQ cleared parasites faster and achieved high cure—strong antiparasitic data.
- Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria
PubMed ID: 23175556
Direct parasitological outcome data (parasite half‑life, PCT) though resistance reduced effect in some regions.
- Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP
PubMed ID: 22303437
RCT in Afghan refugees: adding artesunate markedly reduced treatment failures and gametocyte carriage.
- Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial
PubMed ID: 22586253
RCT: arterolane+piperaquine (artemisinin-class combo) matched standard ACT with rapid parasite clearance and high cure.
- Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana
PubMed ID: 23136273
Large cluster RCT: community delivery of artesunate–amodiaquine substantially reduced under‑5 mortality.
- Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations
PubMed ID: 22554024
Pooled pediatric trials: dihydroartemisinin–piperaquine generally more effective than artesunate–amodiaquine.
- In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam
PubMed ID: 23101492
Randomized trial in Vietnam: artesunate/DHA–piperaquine gave rapid parasite clearance though some delayed clearances noted.
- Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age
PubMed ID: 22966124
Primaquine + artesunate randomized trial markedly reduced early P. vivax recurrences.
- Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria
PubMed ID: 22546009
Safety analysis: chlorproguanil–dapsone±artesunate associated with significant early Hb drops, important for clinical use of artemisinin combos.
- Therapeutic efficacy of artesunate-amodiaquine combinations and the plasma and saliva concentrations of desethylamodiaquine in children with acute uncomplicated Plasmodium falciparum malaria
PubMed ID: 21192244
Clinical efficacy of artesunate–amodiaquine in children confirmed; measurable partner metabolite PK.
- Therapeutic efficacy of artemisinin combination therapies and prevalence of S769N mutation in PfATPase6 gene of Plasmodium falciparum in Kolkata, India
PubMed ID: 23711703
Kolkata surveillance: artesunate-based ACTs remained highly effective; no key resistance mutation detected.
- Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China
PubMed ID: 24215565
Randomized non‑inferiority trial: 3‑day artemisinin–naphthoquine as effective as chloroquine–primaquine for vivax with faster clearance.
- Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance
PubMed ID: 24354627
Two‑year surveillance: three ACTs including artesunate-based regimens highly effective with rapid clearance and high cure rates.
- The effect of an anti-malarial subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a cluster-randomized, controlled trial
PubMed ID: 23452547
Operational trial: ACT subsidy+training increased private‑sector AL availability and appropriate dispensing (improves access to artemisinin therapy).
- Artesunate/amodiaquine malaria treatment for Equatorial Guinea (Central Africa)
PubMed ID: 23530078
In vivo study: artesunate–amodiaquine gave ~97% 28‑day cure in children with falciparum malaria.
- A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia
PubMed ID: 23926329
RCT: both DHP+PQ and ASAQ+PQ gave high 42‑day cure rates for P. vivax.
- High adherence to antimalarials and antibiotics under integrated community case management of illness in children less than five years in eastern Uganda
PubMed ID: 23555980
CHW delivery study: high adherence to artemether–lumefantrine, supports effective community antimalarial use.
- Prophylactic and therapeutic effects of a novel granulated formulation of Artemisia extract on broiler coccidiosis
PubMed ID: 23868546
Poultry coccidiosis study: Artemisia/artemisinin reduced mortality, lesions and oocyst counts (strong antiparasitic effect in animals).
- Efficacy of Quinine versus Artemether in the treatment of severe malaria
PubMed ID: 23787519
Severe pediatric malaria RCT: artemether cleared parasites faster than quinine (supports antimalarial utility).
- Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial
PubMed ID: 25493596
Large RCT in HIV‑exposed Ugandan children showing large reductions in malaria incidence with monthly DP.
- Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial
PubMed ID: 25093754
Large RCT in young Ugandan children: monthly DP substantially reduced malaria incidence and asymptomatic parasitaemia.
- Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso
PubMed ID: 25267980
Triple therapy with artesunate reduced gametocytes substantially (effective against transmission stages).
- Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial
PubMed ID: 24621953
High‑quality RCT: monthly DP IPTm nearly eliminated malaria episodes and parasite carriage in schoolchildren (very strong evidence).
- Spread of artemisinin resistance in Plasmodium falciparum malaria
PubMed ID: 25075834
Multisite study documenting widespread artemisinin resistance in SE Asia (major implication for antimalarial protection effectiveness).
- Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children
PubMed ID: 24943722
Adding artesunate improved parasite clearance and avoided day‑3 positivity.
- Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial
PubMed ID: 24667662
2‑ vs 3‑day DP had similar Day‑42 efficacy but concerns about recrudescence and QTc prolongation; relevant to regimen optimization and protection.
- Comparison of artesunate and quinine in the treatment of severe Plasmodium falciparum malaria at Kassala hospital, Sudan
PubMed ID: 24820465
IV artesunate faster parasite and fever clearance vs quinine in severe malaria — strong therapeutic evidence.
- Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia
PubMed ID: 26654101
Randomized trial showing high relapse prevention for P. vivax when primaquine is used with artemisinin combinations.
- Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial
PubMed ID: 26429700
Large RCT in pregnancy: DHA‑PQP IPT sharply reduced malaria at delivery, clinical episodes and anaemia.
- [Comparison of the effectiveness of artemether and quinine for treatment of severe malaria in children, Bangui, Central African Republic]
PubMed ID: 25925807
Artemether effective for severe malaria with rapid parasite clearance—direct antimalarial efficacy.
- A randomized trial of the efficacy of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital, Cameroon
PubMed ID: 26520401
Artesunate showed faster parasite and fever clearance versus quinine in severe pediatric malaria.
- Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
PubMed ID: 26603174
Artesunate‑mefloquine cleared P. knowlesi parasites faster and reduced anaemia risk vs chloroquine.
- Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children
PubMed ID: 26403465
Higher piperaquine exposure from monthly DHA‑PQP strongly correlated with greater protection against malaria.
- Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study
PubMed ID: 26342427
High day‑28 PCR‑corrected cure rates for artesunate+ferroquine indicate robust antimalarial efficacy.
- Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan
PubMed ID: 26016871
RDTs increased appropriate use of ACTs and thus improved antimalarial treatment effectiveness; indirect evidence.
- Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
PubMed ID: 25966781
Healthy‑volunteer PK study informs safety/exposure of piperaquine (partner drug) relevant to appropriate antimalarial use; indirect to infection control.
- Efficacy of a novel sublingual spray formulation of artemether in African children with Plasmodium falciparum malaria
PubMed ID: 26303805
Sublingual artemether achieved much faster parasite clearance than IV quinine in children—strong antimalarial effect.
- The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial
PubMed ID: 25739769
RDT rollout to private shops reduced unnecessary ACT sales and increased correct targeting—improves antimalarial protection programmatically.
- Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
PubMed ID: 25918149
Seasonal chemoprevention with DHAPQ/SPAQ protects against clinical malaria; DHAPQ is an artemisinin‑partner regimen.
- Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria
PubMed ID: 25801552
Sublingual artemether in children yields adequate exposures and rapid parasite clearance—supports antimalarial protection.
- Introducing rapid diagnostic tests for malaria into registered drug shops in Uganda: lessons learned and policy implications
PubMed ID: 26573910
Subsidized RDTs plus training markedly improved ACT targeting in shops — important programmatic antimalarial benefit.
- A Cluster Randomised Trial Introducing Rapid Diagnostic Tests into Registered Drug Shops in Uganda: Impact on Appropriate Treatment of Malaria
PubMed ID: 26200467
Large cluster RCT: making RDTs available in drug shops greatly reduced ACT overuse and improved correct treatment.
- Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy
PubMed ID: 26962728
Monthly DP in pregnancy markedly reduced maternal and placental malaria — very strong antimalarial protection.
- Appropriate targeting of artemisinin-based combination therapy by community health workers using malaria rapid diagnostic tests: findings from randomized trials in two contrasting areas of high and low malaria transmission in south-western Uganda
PubMed ID: 27383558
CHWs using RDTs resulted in correct ACT targeting across transmission settings—strong programmatic antimalarial protection.
- Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial
PubMed ID: 26757276
Simplified intramuscular artesunate regimen non‑inferior for parasite clearance—practical antimalarial regimen.
- Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial
PubMed ID: 27988484
Artesunate–amodiaquine outperformed chloroquine for P. vivax with fewer recurrences—strong antimalarial efficacy.
- Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial
PubMed ID: 26921676
Periodic artemether adjunct to praziquantel reduced Schistosoma mansoni reinfection—direct antiparasitic benefit.
- Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial
PubMed ID: 27923947
Large cluster‑randomized MDA with DHAp produced ~93% decline in child parasite prevalence in low‑transmission areas (strong antimalarial protection).
- Malaria burden and anti-malarial drug efficacy in Owando, northern Congo
PubMed ID: 26743431
ACTs (ASAQ, AL) remained highly effective for uncomplicated falciparum malaria in children (clinical antimalarial protection).
- The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial
PubMed ID: 27825738
Primaquine added to DHAP significantly reduced gametocyte prevalence — strong antiparasitic/transmission effect.
- Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial
PubMed ID: 27107287
Artesunate‑mefloquine cured chloroquine‑resistant P. vivax with 0% treatment failure (powerful antimalarial efficacy).
- Four artemisinin-based treatments in African pregnant women with malaria
PubMed ID: 27895848
Large trial in pregnant women showed high efficacy of ACTs (including DP) against malaria—direct infection control.
- Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction
PubMed ID: 26917051
AS+SP maintained high PCR‑corrected cure rates for falciparum malaria in Afghanistan—direct infection treatment evidence.
- Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10
PubMed ID: 27067196
Monthly DP chemoprevention reduced malaria episodes by 55% overall and up to 97% with high adherence (strong protective effect).
- Pre-referral Rectal Artesunate Treatment by Community-Based Treatment Providers in Ghana, Guinea-Bissau, Tanzania, and Uganda (Study 18): A Cluster-Randomized Trial
PubMed ID: 27941110
Mothers trained to give prereferral rectal artesunate increased local treatment coverage, improving timely infection treatment at community level.
- Risk factors for Plasmodium falciparum and Plasmodium vivax gametocyte carriage in Papua New Guinean children with uncomplicated malaria
PubMed ID: 27056132
Paediatric trial showed baseline factors and ACT regimen influenced gametocytaemia (transmission/infection dynamics).
- A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam
PubMed ID: 26856909
DHA‑PPQ cleared parasites faster and reduced recurrences vs chloroquine (clear protective/treatment advantage).
- Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial
PubMed ID: 26906747
Primaquine + ACT greatly reduced infectivity to mosquitoes (key for blocking malaria transmission).
- Economic evaluation of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital-Cameroon: a cost analysis
PubMed ID: 27923381
Artesunate yielded faster parasite reduction and shorter hospital stays vs quinine (effective antimalarial therapy).
- Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo
PubMed ID: 27280792
ASAQ cured most children by PCR at 42 days though reinfection common—clinical efficacy against infection.
- Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial
PubMed ID: 28591198
Primaquine added to DHP rapidly reduced gametocytes and blocked mosquito infections (strong antiparasitic/transmission effect).
- Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial
PubMed ID: 28556586
DHA‑PPQ in pregnancy was non‑inferior to ASAQ with similar safety and fewer adverse effects (effective antimalarial option).
- Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial
PubMed ID: 29281988
Artesunate cleared parasites faster than quinine in children with severe malaria—improves infection control speed.
- A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria
PubMed ID: 29121061
Tafenoquine high-dose achieved high Day-28 parasite clearance for P. vivax — strong antiparasitic evidence.
- Expanding access to parasite-based malaria diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment
PubMed ID: 28049481
Training shops to do RDTs increased testing and improved treatment targeting — enhances real‑world antimalarial protection through correct therapy.
- Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants
PubMed ID: 29061746
Dispersible DHA–piperaquine in children was highly efficacious with good tolerability — strong antimalarial protection evidence.
- Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention
PubMed ID: 28187497
Pregnancy and efavirenz substantially lowered DHA and piperaquine exposures — affects antiparasitic drug exposure and likely efficacy.
- Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial
PubMed ID: 28605472
Single low-dose primaquine markedly cut gametocyte carriage — potent antiparasitic/gametocytocidal effect.
- A Molecular Assay to Quantify Male and Female Plasmodium falciparum Gametocytes: Results From 2 Randomized Controlled Trials Using Primaquine for Gametocyte Clearance
PubMed ID: 28931236
Single low-dose primaquine rapidly sterilized infections and shortened gametocyte carriage — very strong antiparasitic support.
- Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda
PubMed ID: 29244829
Economic analysis showed mRDTs in shops improved targeting at low health‑system cost — supports efficient antimalarial protection.
- Use of malaria rapid diagnostic tests by community health workers in Afghanistan: cluster randomised trial
PubMed ID: 28683750
CHW-delivered RDTs greatly reduced inappropriate antimalarial use and improved targeting — supports better infection management.
- Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine
PubMed ID: 28818049
Artesunate generated many once-infected RBCs and was clinically effective with rare severe delayed anemia — strong antiparasitic action.
- Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial
PubMed ID: 29361939
CQ or ACTs plus primaquine effective short-term for P. vivax — direct antiparasitic outcomes.
- Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial
PubMed ID: 30016328
Frequent DP lowered placental malaria (antiparasitic maternal benefit) though infant effects complicated overall interpretation.
- Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW
PubMed ID: 29020373
AL achieved faster parasite clearance than chloroquine in P. knowlesi — clear antiparasitic advantage.
- Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya
PubMed ID: 30016316
CHW testing plus diagnosis‑dependent ACT voucher increased testing and targeted ACTs — supports improved infection control.
- Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial
PubMed ID: 29422384
Primaquine or methylene blue nearly eliminated mosquito infectivity when added to therapy — strong antiparasitic/gametocytocidal evidence.
- Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial
PubMed ID: 29973212
Repeated: high efficacy of ACTs in pregnancy against falciparum malaria.
- Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar
PubMed ID: 29996844
Extending AL to 5 days maintained efficacy in area with artemisinin resistance concerns — supports antiparasitic durability.
- Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs
PubMed ID: 30085149
Primaquine enantiomer PK and interactions with partner drugs affect antiparasitic exposure and activity.
- Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine
PubMed ID: 29547881
Piperaquine exposure target linked to near elimination of infection in IPTp — directly informs antiparasitic protection.
- Molecular Detection of Residual Parasitemia after Pyronaridine-Artesunate or Artemether-Lumefantrine Treatment of Uncomplicated Plasmodium falciparum Malaria in Kenyan Children
PubMed ID: 30105967
Demonstrates substantial submicroscopic residual parasitemia after ACTs — indicates limits to antiparasitic clearance.
- A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages
PubMed ID: 29522113
Three rounds of MDA with DHA–piperaquine sharply reduced clinical falciparum cases — strong antiparasitic population impact.
- Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial
PubMed ID: 29661635
Monthly school IPT with DP modestly reduced parasite measures at community level — some protection.
- Parasite reduction ratio one day after initiation of artemisinin-based combination therapies and its relationship with parasite clearance time in acutely malarious children
PubMed ID: 30522524
Early parasite‑reduction ratios provide early predictive measures of treatment success — helps assess antimalarial protection.
- Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial
PubMed ID: 30376860
IV artesunate produced very rapid parasite clearance in severe malaria — robust antiparasitic effect.
- Plasmodium falciparum gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment
PubMed ID: 29866116
PA showed slightly longer submicroscopic female gametocyte carriage than AL — relevant to antiparasitic/gametocyte dynamics.
- Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial
PubMed ID: 29866192
Randomized trial showing AL had higher adherence and fewer AEs vs AQAS—supports effective antiparasitic use in practice.
- Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL)
PubMed ID: 30125353
Ivermectin with DP produced prolonged mosquitocidal activity—vector control that reduces parasite transmission.
- The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos
PubMed ID: 30390647
MDA substantially reduced P. falciparum reservoirs—direct antiparasitic population‑level effect.
- Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria
PubMed ID: 29976228
In pregnant Nigerian women, ISTp with AL was non‑inferior to IPTp‑SP for preventing severe maternal anaemia and lowered parasitaemia.
- Therapeutic and Transmission-Blocking
Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia
PubMed ID: 29798745
DHA‑PPQ cleared P. vivax and reduced recurrences and transmission—strong antiparasitic findings.
- Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria
PubMed ID: 29889239
CQ+primaquine nearly eliminated relapses of P. vivax for a year—direct radical cure/antiparasitic evidence.
- Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger
PubMed ID: 29370844
High cure rates across ACTs in Niger—solid antiparasitic efficacy data.
- Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials
PubMed ID: 29324864
Single low‑dose primaquine caused small transient Hb declines in G6PDd men but no severe harm — safety data relevant to mass anti‑infection use.
- High efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma Districts, Tanzania
PubMed ID: 29996849
AL and DP remained highly effective in Tanzanian children—antiparasitic clinical evidence.
- A Competing-Risk Approach for Modeling Length of Stay in Severe Malaria Patients in South-East Asia and the Implications for Planning of Hospital Services
PubMed ID: 29562258
Artesunate reduced in‑hospital mortality from severe malaria — strong clinical evidence of life‑saving anti‑infective effect.
- Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan
PubMed ID: 29548285
AS/SP effective for P. falciparum and adding primaquine reduced P. vivax recurrences—clinical antimalarial relevance.
- Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial
PubMed ID: 31600221
MB+AS‑AQ accelerated parasite/gametocyte clearance—enhanced antiparasitic/treatment effect.
- Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial
PubMed ID: 31353217
Monthly DP in pregnancy substantially reduced malaria at delivery and clinical malaria during pregnancy.
- Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial
PubMed ID: 31234865
Low‑dose primaquine added to ACT was tolerated and aimed at transmission‑blocking (antiparasitic effect on gametocytes).
- Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial
PubMed ID: 31307883
Monthly DP nearly eliminated malaria in children while given—clear antiparasitic protective effect.
- Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine
PubMed ID: 31547827
CYP2D6 impairment associated with relapses—pharmacogenetic insight relevant to antiparasitic treatment success.
- Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial
PubMed ID: 30892640
Both ACTs cured most uncomplicated malaria in Rwandan children—clear antiparasitic outcomes.
- Adherence to the referral advice after introduction of rectal artesunate for pre-referral treatment of severe malaria at the community level: a noninferiority trial in the Democratic Republic of the Congo
PubMed ID: 31864376
Pre‑referral rectal artesunate acceptable at community level—relevant to early severe malaria management and infection control.
- Comparison of malaria treatment outcome of generic and innovator's anti-malarial drugs containing artemether-lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
PubMed ID: 30975147
Generic artemether–lumefantrine performed similarly to brand product in treating uncomplicated malaria—supports clinical effectiveness.
- Intermittent preventive treatment of malaria delivered to primary schoolchildren provided effective individual protection in Jinja, Uganda: secondary outcomes of a cluster-randomized trial (START-IPT)
PubMed ID: 31533845
School monthly DP dramatically lowered parasitaemia and gametocytes—robust antiparasitic effect.
- The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial
PubMed ID: 30768615
Targeted DP MDA produced large falls in falciparum prevalence—strong antiparasitic program impact.
- Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial
PubMed ID: 30865632
SMC (antimalarial prophylaxis) produced large reductions in clinical malaria and parasite carriage — strong antiparasitic effect in children.
- Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria
PubMed ID: 30952158
DHA‑piperaquine gave faster fever/parasite clearance vs chloroquine and primaquine regimens prevented P. vivax relapse — clinical anti‑infective effects.
- Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine
PubMed ID: 31795967
Low piperaquine exposures associated with doubled recurrence risk — highlights exposure–response for antiparasitic effect.
- Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children
PubMed ID: 30418593
DHA‑piperaquine markedly reduced recurrence vs AL in Ugandan children — clear antimalarial protection.
- Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children
PubMed ID: 30696903
PK/PD analyses predict improved protection with higher piperaquine dosing and longer SMC — modelling supports better anti‑infective strategies.
- In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
PubMed ID: 31906948
ASAQ reduced recurrent infections much more than AL over 42 days — strong antimalarial post‑treatment protection signal.
- Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal
PubMed ID: 32483161
Artemisinin combinations remained highly effective with rapid clearance and no resistance markers detected — excellent antimalarial protection.
- A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa
PubMed ID: 31818818
Extending AL to 5 days in pregnancy increased lumefantrine exposure and maintained 100% PCR‑corrected cures — improved antimalarial exposure in pregnant women.
- Cost-Effectiveness of Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine for Malaria Prevention in Southern Province, Zambia: Results of a Community-Randomized Controlled Trial
PubMed ID: 32618249
Mass DHA‑piperaquine treatment averted infections/cases, a scalable antiparasitic intervention in higher transmission areas.
- Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial
PubMed ID: 32966290
Randomized trial: adding DHP to praziquantel raised cure and egg reduction for intestinal schistosomiasis — direct antiparasitic benefit beyond malaria.
- Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
PubMed ID: 32171078
Triple‑drug ACTs restored very high PCR‑corrected cure rates in areas with multidrug resistance — potent antimalarial protection.
- Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial
PubMed ID: 32334702
Cluster trial: targeted drug treatment plus focal spraying sharply cut infections — population antiparasitic impact.
- Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial
PubMed ID: 32580771
In Guinea ASAQ and AL were highly effective with rapid clearance — robust antimalarial efficacy.
- Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether-lumefantrine
PubMed ID: 31964380
Primaquine on day 1 with AL tended to clear gametocytes faster — reduces transmission potential (anti‑infective relevance).
- Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial
PubMed ID: 32772921
IPTp with DHA‑piperaquine modestly reduced infant malaria overall (stronger in male infants) — moderate anti‑infective downstream effect.
- Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and Plasmodium falciparum Clearance in Southern Province, Zambia
PubMed ID: 32618267
Large MDA program achieved high adherence and rapid clearance — operational antiparasitic evidence.
- The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR
PubMed ID: 31900172
Post‑MDA 14‑day primaquine prevented P. vivax relapses for 12 months — strong antimalarial protection against relapse.
- Malaria Chemoprevention in the Postdischarge Management of Severe Anemia
PubMed ID: 33264546
Monthly postdischarge DHA‑piperaquine markedly reduced readmission or death in children after severe anemia — reduced subsequent infectious events.
- Prevalence of Plasmodium falciparum and Non-falciparum Infections by Photo-Induced Electron Transfer-PCR in a Longitudinal Cohort of Individuals Enrolled in a Mass Drug Administration Trial in Southern Province, Zambia
PubMed ID: 32618252
Large PET‑PCR surveillance demonstrated many low‑density infections missed by RDT/microscopy — important for understanding limits of protection from test‑and‑treat programs.
- A Longitudinal Cohort to Monitor Malaria Infection Incidence during Mass Drug Administration in Southern Province, Zambia
PubMed ID: 32618245
Cohort nested in MDA trial showed reduced PCR‑detected infections and delayed first infection following MDA.
- Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia
PubMed ID: 32618247
Very large community RCT: MDA + scale‑up led to major declines in malaria prevalence and case incidence.
- Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
PubMed ID: 32537072
Comparative efficacy data showing differing unadjusted cure rates for AL vs ASAQ relate to antiparasitic performance.
- Significant Efficacy of a Single Low Dose of Primaquine Compared to Stand-Alone Artemisinin Combination Therapy in Reducing Gametocyte Carriage in Cambodian Patients with Uncomplicated Multidrug-Resistant Plasmodium falciparum Malaria
PubMed ID: 32179526
Single low‑dose primaquine added to DP reduced gametocyte carriage rapidly — reduces transmission potential, aiding protection.
- Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials
PubMed ID: 32023293
MDA in Greater Mekong caused marked short‑term P. vivax reductions, though effects rebounded without radical cure.
- Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania
PubMed ID: 32046718
PK study in children showed high 28‑day cure rates for AL despite variable day‑7 lumefantrine levels — supports therapeutic protection in practice.
- A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border
PubMed ID: 34107963
DP showed highest PCR‑corrected cure for P. falciparum in pregnancy — strong antiparasitic efficacy.
- Imatinib augments standard malaria combination therapy without added toxicity
PubMed ID: 34436509
Imatinib + DHA‑PPQ sped parasite clearance compared with DHA‑PPQ alone — enhanced antiparasitic effect.
- Reactive, self-administered malaria treatment against asymptomatic malaria infection: results of a cluster randomized controlled trial in The Gambia
PubMed ID: 34098984
Reactive self‑administered DP showed limited population impact overall but reduced infections in children <5 and in villages with cases.
- Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa
PubMed ID: 33526485
Rectal artesunate rapidly achieves parasiticidal concentrations and initiates parasite clearance in children.
- Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial
PubMed ID: 33891721
Monthly DP in pregnancy substantially reduced placental malaria, maternal infection at delivery and low birth weight.
- Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
PubMed ID: 34111412
Arterolane combinations achieved high cure rates in children — effective antiparasitic therapy.
- Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial
PubMed ID: 34147154
MDA with DP in Myanmar hotspots produced very large short‑term reductions in P. falciparum prevalence.
- Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children
PubMed ID: 34795281
Piperaquine PK modeling supports DP schedules giving protective drug levels—antiparasitic prevention rationale.
- Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018
PubMed ID: 34732201
Large therapeutic efficacy trial: ACT combos cured >95% of children and cleared parasites rapidly — direct antimalarial protection evidence.
- Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial
PubMed ID: 35995135
Intermittent ACT-based preventive therapy in schoolchildren reduced prevalence of P. falciparum substantially — protective effect.
- Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial
PubMed ID: 36215323
Monthly DP reduced asymptomatic parasitaemia by ~79% in sickle cell children — protective regimen against malaria carriage.
- Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial
PubMed ID: 36462528
Single low-dose primaquine added to ACTs was safe and rapidly lowered gametocyte carriage in African children — supports antimalarial programs.
- Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
PubMed ID: 36451216
AL and DHA–PPQ remained highly effective in Ethiopia with rapid clearance and 100% ACPR in per-protocol analyses — strong protection evidence.
- Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial
PubMed ID: 35028628
Adding single low-dose primaquine to ACTs rapidly halted transmission to mosquitoes — important adjunct to antimalarial strategies.
- Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women
PubMed ID: 34864925
Monthly DHA–PPQ in pregnancy reduced malaria but caused small QTc increases tied to piperaquine — efficacy balanced by safety consideration.
- Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial
PubMed ID: 35544095
Single low tafenoquine dose with DHA–PPQ cleared gametocytes and stopped mosquito transmission by day 7 — complements antimalarial protection.
- High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine
PubMed ID: 34216470
Detection of K13 resistance mutations (R561H) linked to delayed clearance — important antiparasitic resistance surveillance finding (reduces expected effect).
- Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): an open-label randomized trial
PubMed ID: 35109841
Artemether–lumefantrine produced very high PCR-corrected ACPR and rapid parasite clearance vs comparator — direct antimalarial efficacy.
- Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial
PubMed ID: 37979594
High‑dose primaquine given with schizontocidal therapy reduced subsequent P. vivax recurrences — extends antimalarial protection post-treatment.
- Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial
PubMed ID: 37474234
Large school-based trial: intermittent artemisinin-based treatment reduced infection prevalence and improved haemoglobin at 12 months — protection evidence.
- Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial
PubMed ID: 36913959
Monthly DP in pregnancy markedly lowered maternal malaria and placental infection though associated with adverse newborn outcomes.
- Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar
PubMed ID: 37646608
Direct, well‑powered therapeutic efficacy trial showing high cure rates for uncomplicated P. falciparum with artemisinin‑based combinations.
- Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis
PubMed ID: 36919202
PK/PD modeling in Ugandan trials links piperaquine exposure with protection against malaria; shows exposure–protection relationship.
- Therapeutic response to artemisinin combination therapies among individuals with Plasmodium falciparum single infection vs mixed Plasmodium species infections: a retrospective posthoc analysis in Kisumu County, western Kenya
PubMed ID: 37061211
Comparative analysis showing faster parasite clearance with certain ACTs and longer post‑treatment protection with DP.
- Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial
PubMed ID: 38224706
Monthly DP with co‑trimoxazole reduced maternal malaria endpoints in pregnant women with HIV — robust protective effect.
- Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial
PubMed ID: 38177851
Randomized trial repurposing artesunate‑mefloquine showed non‑inferior parasitological efficacy vs praziquantel for schistosomiasis.
- Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial
PubMed ID: 39699212
Randomized Kenyan trial: several ACT+PZQ combos provided comparable egg‑reduction rates — supports antiparasitic utility.
- Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial
PubMed ID: 38224710
Adding monthly DP to co‑trimoxazole in pregnant women on dolutegravir cut malaria infections/placental malaria substantially.
- Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali
PubMed ID: 37682871
Monthly DHA‑piperaquine markedly reduced clinical malaria incidence and parasitemia in schoolchildren — strong prophylactic evidence.
- Artemether-lumefantrine-amodiaquine or artesunate-amodiaquine combined with single low-dose primaquine to reduce Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a five-arm, phase 2, single-blind, randomised controlled trial
PubMed ID: 39701119
Randomized trial demonstrated that adding low‑dose primaquine to ACTs rapidly blocks transmission to mosquitoes — reduces onward infections.
- Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial
PubMed ID: 38943214
Large trial found adding an ACT to praziquantel did not clearly improve intestinal schistosomiasis cure but was comparable for urinary species.
- Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
PubMed ID: 38714692
Molecular study showed extended AL reduced persistent ring‑stage parasites — evidence relevant to improving infection clearance.
- Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women
PubMed ID: 39402742
Coadministration of DP+SP reduced partner‑drug exposures — clinically relevant to protection efficacy in pregnancy.
- Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial
PubMed ID: 39718172
Weekly DP in children with sickle cell anaemia reduced clinical malaria by ≈80% — strong prevention signal.
- The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial
PubMed ID: 39424572
Monthly DHA‑PQ removed most malaria infections in schoolchildren (direct infection reduction).
- Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021
PubMed ID: 38570791
Therapeutic efficacy study showing AL and DP remain highly effective in children — strong antimalarial infection control evidence.
- Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers
PubMed ID: 39363296
New injectable artesunate formulation had combined ART+DHA exposure similar to existing product — supports clinical antimalarial use.
- Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials
PubMed ID: 39695728
Randomized study showed parasite clearance with both regimens and differing prophylactic durations.
- Dihydroartemisinin-piperaquine effectiveness for seasonal malaria chemoprevention in settings with extended seasonal malaria transmission in Tanzania
PubMed ID: 38273019
Large operational SMC program with DHA‑PPQ associated with lower malaria prevalence.
- Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study
PubMed ID: 39344281
Ganaplacide+lumefantrine PK study shows no interaction—supports combination therapies' effective drug exposures.
- Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda
PubMed ID: 40966190
Monthly DP (dihydroartemisinin partner) prevented malaria effectively in pregnancy — antiparasitic prevention effect.
- Targeting malaria in high-risk populations in low endemic regions in northern Namibia: a quasi-experimental controlled trial to reduce malaria in seasonal agricultural workers and cattle herders
PubMed ID: 39961693
Targeted worksite interventions increased coverage and reduced malaria prevalence in seasonal workers.
- Decreased dihydroartemisinin-piperaquine protection against recurrent malaria associated with Plasmodium falciparum plasmepsin 3 copy number variation in Africa
PubMed ID: 40102390
Increasing plasmepsin CNV reduced DHA‑PPQ post‑treatment prophylactic duration—impact on protection durability.
- Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC
PubMed ID: 39985024
Pyronaridine‑artesunate performed comparably to IPTp‑SP for reducing parasitemia at delivery in a trial.
- Effectiveness of sulfadoxine-pyrimethamine plus amodiaquine and dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial
PubMed ID: 39826559
SMC DHA‑PPQ produced very large reductions in malaria incidence in young children—direct antiparasitic evidence.
- Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial
PubMed ID: 39799956
MDA with DHA‑PPQ+primaquine gave large short‑term reductions in parasite prevalence.
- Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria
PubMed ID: 41052792
Pooled PK showed amodiaquine did not alter artemether‑lumefantrine exposures—supports coadministration efficacy.
- Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone
PubMed ID: 41080970
Molecular surveillance showing lack of validated pfK13 artemisinin resistance supports ongoing antiparasitic utility.
- Single-step versus conventional injectable artesunate for severe malaria in children: an open label, non-inferiority randomized clinical trial, Democratic Republic of the Congo and United Republic of Tanzania
PubMed ID: 41415126
One‑step artesunate was operationally superior with equivalent parasite clearance and safety—practical infection control benefit.
- Efficacy and Safety of Artesunate + Amodiaquine and Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Madagascar, 2020
PubMed ID: 41187342
Artemisinin‑based combos produced >99% PCR‑corrected cure—strong antiparasitic support.
- Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial
PubMed ID: 20417857
Phase 3 data: pyronaridine–artesunate non‑inferior to artemether–lumefantrine with very high day‑28 cure.
- Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial
PubMed ID: 23113947
Pediatric noninferiority trial showing high cure rates with pyronaridine–artesunate granules.
- Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children
PubMed ID: 23190222
HIV protease inhibitor boosting of partner drug exposure reduced malaria incidence—relevant to post‑treatment protection.
- Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
PubMed ID: 26601738
Pyronaridine‑artesunate retained high efficacy and rapid parasite clearance on re‑treatment — strong antiparasitic evidence.
- Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria
PubMed ID: 28722611
Small adult trial: artesunate combinations cleared parasites rapidly (no recurrence through day 28) — direct infection control evidence.
- Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
PubMed ID: 29764419
Pyronaridine–artesunate non‑inferior with high cure and fast parasite clearance — strong antiparasitic data.
- Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
PubMed ID: 29606364
Two‑year multicenter trial: pyronaridine–artesunate remained non‑inferior and effective for repeated uncomplicated malaria treatment.
- Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial
PubMed ID: 33983371
High day‑28 adequate parasitological response and rapid clearance in asymptomatic infections treated with pyronaridine–artesunate.
- A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children
PubMed ID: 9598454
Artemether–lumefantrine cleared parasites faster and suppressed gametocytes compared with SP.
- Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria
PubMed ID: 9449273
Artemisinin combos highly effective in multidrug‑resistant falciparum malaria with superior longer‑term cure for some regimens.
- Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients
PubMed ID: 9862244
Population PK study: lumefantrine exposure predicts cure and artemether/DHA exposure predicts faster parasite clearance — mechanistic support for infection control.
- Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years
PubMed ID: 9657513
Artemether–lumefantrine produced dramatically higher cure rates vs chloroquine — very strong antiparasitic evidence.
- Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children
PubMed ID: 9657512
Clinical trial in children demonstrating superior parasite clearance and suppression of reinfection with co‑artemether vs chloroquine.
- Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
PubMed ID: 10403324
Six‑dose artemether–lumefantrine substantially improved 28‑day cure rates — strong antiparasitic/ regimen-optimization evidence.
- A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand
PubMed ID: 10072142
Artemether+benflumetol cleared parasites faster than mefloquine but had lower durable 28‑day cure (mixed result for protection).
- The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France
PubMed ID: 10418762
Faster parasite clearance in travellers with artemisinin combo — direct antiparasitic effect.
- Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria
PubMed ID: 10681341
PK/PD evidence links lumefantrine exposure to cure — important mechanistic antiparasitic support.
- A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India
PubMed ID: 11037786
Co‑artemether produced a very large improvement in 28‑day cure vs chloroquine (95.4% vs 19.7%).
- Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria
PubMed ID: 11132386
Artemether–lumefantrine highly effective and well tolerated in multidrug‑resistant malaria.
- [Clinical comparative trial of co-artemether and benflumetol (two formulations) in the treatment of falciparum malaria]
PubMed ID: 12567694
Co‑artemether delivered faster parasite clearance and slightly higher 28‑day cure than comparator.
- Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers
PubMed ID: 11009045
Healthy‑volunteer PK/ECG study supports safe coadministration scenarios relevant to therapy; indirect protection implication.
- A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand
PubMed ID: 11463111
Effective and well-tolerated against multidrug‑resistant P. falciparum — strong antiparasitic relevance.
- Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand
PubMed ID: 12971556
Short DNP regimen provided cure rates comparable to 3‑day AL — antiparasitic effectiveness.
- Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic
PubMed ID: 15486837
Large Laos trial: artemisinin‑based combinations produced very high 42‑day cure rates and faster parasite clearance vs chloroquine+SP.
- Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic
PubMed ID: 15548313
ACT regimens cleared malaria rapidly with excellent cure rates — direct antiparasitic data.
- Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh
PubMed ID: 16095643
Artemisinin combos were far more effective than CQ+SP and prevented gametocytes — strong antiparasitic evidence.
- A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand
PubMed ID: 16179089
On Thailand–Myanmar border both ACTs highly efficacious; artemether–lumefantrine cleared parasites faster.
- Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial
PubMed ID: 15850631
Large pediatric effectiveness trial: artemether–lumefantrine had the lowest failure/recrudescence rates.
- Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania
PubMed ID: 16163624
Pediatric comparison: both artesunate–amodiaquine and artemether–lumefantrine cured well; AL provided stronger protection against reinfection.
- Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial
PubMed ID: 15850630
High PCR‑adjusted cure rates show strong antiparasitic activity of AL.
- Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial
PubMed ID: 16704735
Rapid clearance and improved anemia in children treated with ACTs supports antiparasitic activity.
- A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali
PubMed ID: 17038684
RCT evidence of antiparasitic efficacy for artemisinin combinations.
- Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda
PubMed ID: 16854236
PK/clinical link: higher lumefantrine levels reduced re‑infections — antiparasitic exposure–effect relationship.
- [Coartem and fansimef in the treatment of falciparum malaria]
PubMed ID: 16866137
Comparative series with high 28‑day cure rates and rapid parasite/fever clearance.
- The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children
PubMed ID: 17013650
Children RCT demonstrating clinical resolution of malaria‑related hepatomegaly and parasite clearance.
- Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults
PubMed ID: 16923176
Large trial: AL superior to SP with fewer parasitological failures.
- Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo
PubMed ID: 17125496
High PCR‑corrected cure rates in children indicate antiparasitic efficacy.
- High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola
PubMed ID: 16837721
RCT in children: high efficacy and reduced recurrent infection.
- Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria
PubMed ID: 17194834
Treatment‑driven selection of pfmdr1 alleles alters parasite susceptibility — mechanistic antiparasitic relevance.
- A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda
PubMed ID: 17005222
AL cleared parasites and achieved higher ACPR vs comparator in children.
- HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria
PubMed ID: 16960779
Cohort: HIV and low CD4 increased recurrent infection/recrudescence after treatment — immune interaction with infection control.
- Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand
PubMed ID: 17570973
AL+primaquine effective for vivax — antiparasitic against P. vivax when combined with primaquine.
- A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan
PubMed ID: 17631681
Both combinations PCR‑corrected efficacies >~91% — antiparasitic activity.
- Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial
PubMed ID: 17519410
Community trial: AL showed lowest failure rates and population benefits — very strong antiparasitic evidence.
- Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso
PubMed ID: 17990228
AL cleared infections but had higher recurrent parasitaemia vs other regimens — antiparasitic effect present but shorter post‑treatment prophylaxis.
- Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal
PubMed ID: 17570848
Artemisinin combos rapidly cleared parasites and reduced gametocyte carriage — strong antiparasitic effect.
- Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania
PubMed ID: 17996121
AL produced 100% PCR-corrected cure in Tanzanian children—direct antimalarial protection evidence.
- Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison
PubMed ID: 17336652
Rapid parasite clearance and lower recurrences with certain partner drugs—strong antiparasitic effect.
- Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal
PubMed ID: 17827354
AL superior to SP in clearing falciparum—clear antiparasitic support.
- Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria
PubMed ID: 17300626
Lower lumefantrine exposure with once‑daily dosing reduced drug exposure and tended to lower cure.
- Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
PubMed ID: 17292769
Higher recurrence after AL in this setting—still antiparasitic but comparative limitations.
- Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria
PubMed ID: 17690392
AL produced faster parasite clearance in Nigerian children—direct antiparasitic effect.
- Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
PubMed ID: 18796142
Safety data in treated patients (no ototoxicity) supports continued safe use to fight infections.
- A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda
PubMed ID: 19738339
AL and chlorproguanil–dapsone had similar parasite clearance times in pregnant women—antiparasitic evidence.
- Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up
PubMed ID: 18620577
Both regimens cured most children (PCR‑corrected), demonstrating antiparasitic activity.
- A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
PubMed ID: 19017387
Rapid asexual parasite clearance in Kenyan children—strong antiparasitic evidence.
- Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children
PubMed ID: 18547415
Repeated ACT treatments remained effective and safe—supports antiparasitic use over time.
- Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial
PubMed ID: 18926569
Dispersible pediatric AL as effective as crushed tablets—direct antiparasitic evidence.
- A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy
PubMed ID: 19265453
AL was safe but less effective than 7‑day artesunate in pregnancy—some limitations to infection control here.
- Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda
PubMed ID: 18545692
Comparison shows DP had fewer recurrences than AL, but AL remains antiparasitic — comparative context.
- A trial of combination antimalarial therapies in children from Papua New Guinea
PubMed ID: 19064624
AL effective vs P. falciparum in PNG — parasite‑specific efficacy.
- An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria
PubMed ID: 18575626
AS+AQ had fewer parasitological failures than AL in this trial — comparative antiparasitic data.
- Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial
PubMed ID: 18606428
High effectiveness and adherence with AL; day‑7 lumefantrine predicted reinfection—robust antiparasitic data.
- A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children
PubMed ID: 19099594
AL had higher late failure than ASAQ in this trial—antiparasitic effect present but context-dependent.
- A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
PubMed ID: 18981499
Comparable PCR-corrected cures for artesunate–mefloquine and AL—strong antiparasitic support.
- Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children
PubMed ID: 18560227
Marked post-treatment reduction in gametocyte density—antiparasitic/transmission-blocking benefit.
- A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya
PubMed ID: 19102746
High cure rates and parasite/gametocyte clearance for pediatric AL formulations—direct antiparasitic evidence.
- [Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China]
PubMed ID: 18637586
100% cure at 28 days with AL—strong antiparasitic result.
- High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria
PubMed ID: 18346028
High PCR‑corrected cures indicate antiparasitic efficacy.
- Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria
PubMed ID: 19564366
Lower lumefantrine exposure in pregnancy linked to higher recrudescence (antiparasitic concern).
- Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial
PubMed ID: 19366448
Fixed-dose artesunate combinations non-inferior to AL across sites—strong antiparasitic evidence.
- Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
PubMed ID: 19948038
Repeated ACTs generally safe/effective in infants and children—supports antiparasitic use over repeated exposures.
- A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire
PubMed ID: 19575797
One-day artemisinin/naphtoquine gave comparable parasite clearance and day28 cure to AL—antiparasitic support (smaller study).
- Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
PubMed ID: 19877969
DP had fewer early recurrences than AL in infants — informs antiparasitic durability of AL.
- Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda
PubMed ID: 19905933
Prior AQ use associated with parasites less sensitive to AQ (impacts overall antiparasitic landscape).
- Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
PubMed ID: 19709418
High AL effectiveness associated with good adherence—reliable antiparasitic evidence.
- Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
PubMed ID: 19936217
Large non-inferiority trial confirming DHA‑PQP comparable to AL with extended prophylaxis—strong antiparasitic support.
- Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial
PubMed ID: 19469703
High PCR-adjusted effectiveness of artemisinin combos in Beninese children—solid antiparasitic evidence.
- Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial
PubMed ID: 19362361
Home AL distribution reduced parasite prevalence but increased overtreatment — mixed antiparasitic outcome.
- In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
PubMed ID: 19210165
Demonstrated selection of parasite resistance alleles after AL—mechanistic antiparasitic/resistance evidence.
- Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial
PubMed ID: 19622553
AL clearly superior to quinine for cure — strong antiparasitic evidence.
- Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania
PubMed ID: 20713675
PK/PD link between artemether exposure and parasite clearance—mechanistic antiparasitic support.
- Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial
PubMed ID: 20877714
RDT-guided community management including AL reduced inappropriate antimalarial use and increased correct targeting of antimalarials.
- Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast
PubMed ID: 20214761
Large randomized multisite trial showing high ACPR and rapid fever/parasite clearance with artesunate-containing ACTs.
- Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial
PubMed ID: 20557237
Randomized trial: azithromycin-artesunate cured most uncomplicated malaria comparable to AL — supports antimalarial protection.
- A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops
PubMed ID: 20594372
Subsidy increased availability/uptake of ACTs, expanding access to antiparasitic treatment.
- The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso
PubMed ID: 20958888
Clearance occurred but study highlights faster reinfection post-clearance—still demonstrates antiparasitic activity.
- Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
PubMed ID: 20932805
AL cured nearly all uncomplicated malaria infections in pregnancy—direct antiparasitic effect.
- Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects
PubMed ID: 20815879
Dispersible pediatric AL provided similar exposure to crushed tablets supporting effective antiparasitic dosing in children.
- Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan
PubMed ID: 20659392
DHA‑P and AL cured uncomplicated malaria effectively with rapid clearance and high day‑28 PCR-corrected cure rates.
- Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance
PubMed ID: 21092220
RCT shows expected high cure rates and early parasite dynamics — confirms anti-infective effect though highlights early parasitemia transiently.
- Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children
PubMed ID: 20689585
Sustained high ACT efficacy and large declines in malaria incidence over 4 years indicate durable antimalarial protection.
- Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
PubMed ID: 20149235
Programmatic study showing very high adherence to AL under routine conditions, supporting real-world infection control.
- The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria
PubMed ID: 20180933
PK study showing food increases lumefantrine absorption though cure rates remained high—relevant to optimizing effective dosing against infection.
- Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria
PubMed ID: 20889882
RCT safety analysis showing DP caused more vomiting than AL but both remained efficacious—relevant to infection treatment choices.
- Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia
PubMed ID: 21666744
AL performed better than comparator with fewer treatment failures — strong antimalarial protection evidence.
- Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial
PubMed ID: 21427394
High cure rates in children whether supervised or not—supports antiparasitic efficacy of AL.
- Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial
PubMed ID: 21148503
AL cured nearly all uncomplicated malaria cases — direct antimalarial protection evidence.
- Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial
PubMed ID: 22166001
Cluster RCT combining IPT and home management produced 79% protective efficacy vs malaria—strong antimalarial protection.
- The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
PubMed ID: 21655317
Retail subsidy/training increased timely AL use in children, improving antiparasitic coverage.
- Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial
PubMed ID: 21838909
Randomized trial: repeated ASAQ effective vs AL for recurrent episodes — clear anti-infective outcome.
- Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal
PubMed ID: 21740570
DPT regimen non-inferior to AL with rapid parasite clearance—clear antiparasitic support.
- Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa
PubMed ID: 21774826
DP matched AL in efficacy and cleared parasites faster—strong antiparasitic evidence.
- Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
PubMed ID: 22102856
Analysis indicated rising residual parasitemia and late recurrences—relevant to evolving antiparasitic effectiveness concerns.
- Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4-59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial
PubMed ID: 22172305
Post-discharge monthly AL provided significant protective efficacy against death/readmission in children recovering from severe anemia.
- Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria
PubMed ID: 21540395
Randomized trial in Nigerian children showing rapid fever/parasite clearance with artemisinin-based regimens.
- Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges
PubMed ID: 22176931
High 28-day PCR-corrected cure rates (>97%) with AL show robust antiparasitic activity.
- Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
PubMed ID: 21352609
DHA‑piperaquine had substantially fewer re-infections post-treatment — enhanced post‑treatment protection.
- A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial
PubMed ID: 22087077
Very large multicenter randomized comparisons showing consistently high PCR-adjusted cure rates for artemisinin-based combinations — strongest evidence for antimalarial protection.
- Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria
PubMed ID: 21670177
Dispersible pediatric AL provides similar artemisinin exposures — supports antiparasitic dosing in children.
- Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anemia after treatment
PubMed ID: 20683244
ASAQ produced less and shorter anemia than mefloquine — indicates effective antimalarial activity reducing morbidity.
- Comparative feasibility of implementing rapid diagnostic test and microscopy for parasitological diagnosis of malaria in Uganda
PubMed ID: 22182758
Large trial showing RDTs increased testing and reduced unnecessary AL prescriptions—improves targeting of antimalarial therapy.
- Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua kouté, Côte d'Ivoire
PubMed ID: 21214690
Pediatric artesunate‑mefloquine non‑inferior to AL with high cure rates — antimalarial protection in children.
- Oral artesunate-amodiaquine and artemether-lumefantrine in the treatment of uncomplicated hyperparasitaemic Plasmodium falciparum malaria in children
PubMed ID: 21622538
Measured parasite half-life ~1 h with artemisinin combos—demonstrates rapid antiparasitic action.
- Effects of malaria volunteer training on coverage and timeliness of diagnosis: a cluster randomized controlled trial in Myanmar
PubMed ID: 22946985
Cluster RCT of volunteer training increased testing and use of ACTs somewhat — programmatic infection control support (indirect).
- A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate and amodiaquine and artemether-lumefantrine
PubMed ID: 21519221
Simplified artesunate-amodiaquine led to faster parasite clearance and higher cure rates—antiparasitic evidence.
- Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria
PubMed ID: 22232454
High cure rates and objective safety measures in Colombian adults—direct antiparasitic evidence.
- [A randomized clinical trial comparing the effectiveness and tolerability of artemisinine-naphthoquine (Arco®) and artemether-lumefantrine (Coartem®) in the treatment of uncomplicated malaria in Benin]
PubMed ID: 22328063
Single‑dose artemisinin‑naphthoquine cleared parasites faster — direct antiparasitic evidence.
- Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial
PubMed ID: 22631564
ASAQ non‑inferior with rapid parasite clearance.
- No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos
PubMed ID: 22403308
Small Laos study with rapid clearance and no resistance signal — supportive antimalarial evidence.
- Quality and safety of integrated community case management of malaria using rapid diagnostic tests and pneumonia by community health workers
PubMed ID: 22595272
Community health workers used RDTs and gave AL safely — supportive programmatic evidence for treating infections.
- Comparative efficacies of artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps genes in tea gardens of Jalpaiguri District, India
PubMed ID: 22314538
High PCR‑corrected efficacy for artemisinin combinations in Indian setting.
- Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact
PubMed ID: 22764291
Repeated ACT use over 24 months remained highly efficacious at community level—sustained antiparasitic effect.
- Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal
PubMed ID: 23270636
Pediatric suspension non-inferior to AL with high cure rates for uncomplicated falciparum malaria.
- Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial
PubMed ID: 23295878
Adult trial showing artesunate+amodiaquine non-inferior to AL with similarly high cure rates and faster fever resolution.
- A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso
PubMed ID: 23442748
Targeted AL treatment reduced asymptomatic parasitaemia and transiently affected gametocyte carriage—antimalarial protection at population level.
- An open randomized controlled trial to compare the efficacy of two fixed dose combinations of artemesinin based combinations for uncomplicated falciparum malaria in Bangladesh
PubMed ID: 26118157
Direct RCT evidence of high 28‑day cure rates with AL vs artesunate‑amodiaquine in uncomplicated falciparum malaria.
- Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial
PubMed ID: 23441978
PK interactions that alter artemisinin/dihydroartemisinin exposures could affect antiparasitic effectiveness in co‑treated patients.
- Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
PubMed ID: 23866736
Large Liberian trial demonstrating both ACT regimens are generally safe and effective against malaria infections.
- A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya
PubMed ID: 23870627
Pediatric RCT showing high PCR‑corrected efficacy and fewer re‑infections with DP compared to AL.
- Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial
PubMed ID: 23468056
DP produced fewer recurrent parasitemias but longer gametocyte carriage—important antiparasitic tradeoff.
- Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial
PubMed ID: 23866774
Both ASAQ and AL cured malaria reliably in children—strong antiparasitic support.
- In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia
PubMed ID: 23717423
AL cleared P. vivax faster than chloroquine with high adjusted cure rates — antimalarial protection evidence.
- Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria
PubMed ID: 23489465
Two fixed‑dose AL products performed equally — consistent antiparasitic exposures.
- Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial
PubMed ID: 24239324
Primaquine added to AL decreased gametocyte carriage — reduces parasite transmission reservoir.
- Efficacy of artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children
PubMed ID: 24334945
High day‑28 PCR‑corrected cure rates for AL in Nigerian children — strong antimalarial protection.
- The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children
PubMed ID: 23382157
Observational data showing higher gametocyte detection with some regimens — informs antiparasitic strategy.
- Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence
PubMed ID: 23945376
Submicroscopic residual parasitemia after ACT predicted infectivity and recurrence — highlights need for full antiparasitic clearance.
- Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study
PubMed ID: 24010572
New single‑tablet AL formulations are bioequivalent to standard dosing ensuring antiparasitic exposures.
- Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea
PubMed ID: 23403171
Demonstrated rapid parasite clearance in young children with AL — direct antiparasitic evidence.
- Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children
PubMed ID: 23349741
DHA‑piperaquine produced fewer recurrent infections than AL or quinine — strong antiparasitic result.
- [Efficacy and safety of antimalarial combinations for treatment of uncomplicated malaria in children in Bangui, Central African Republic]
PubMed ID: 24122669
High day‑28 PCR‑corrected ACPR with ACTs indicates strong antiparasitic efficacy.
- Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children
PubMed ID: 25246693
High PCR‑corrected cure and rapid parasite clearance in Nigerian children — antiparasitic support.
- Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial
PubMed ID: 24393479
Comparable day‑28 PCR‑corrected cure rates across ACTs support antiparasitic use.
- Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial
PubMed ID: 24494602
Effectiveness under routine conditions with similar PCR‑corrected cure supports antiparasitic performance.
- A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria
PubMed ID: 25236838
SCD children achieved high day‑42 cure rates after ACT — antiparasitic activity retained in comorbidity.
- Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study
PubMed ID: 24472156
Non‑inferiority pediatric trial with high PCR‑corrected ACPR for AL dispersible — antimalarial protection confirmed.
- Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire
PubMed ID: 25409546
Multi‑site RCT showing maintained high day‑42 PCR‑corrected cure rates for AL and AS‑AQ.
- Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial
PubMed ID: 25414262
Ivermectin+AL reduced mosquito survival and estimated transmission potential—addresses parasite transmission reservoir.
- Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial
PubMed ID: 25549086
Artemisinin–naphthoquine provided superior P. vivax control vs AL — strong antiparasitic evidence.
- Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children
PubMed ID: 24732940
Novel fixed‑dose formulations showed effective parasite clearance supporting antiparasitic use.
- Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria
PubMed ID: 24468007
Dataset documents regimen‑specific early parasite clearance patterns—direct antiparasitic relevance.
- Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing artemether-lumefantrine: effect on dispenser knowledge and patient adherence
PubMed ID: 25002300
Implementation study affecting dispenser advice on drug administration (fat intake) — influences antiparasitic drug exposure and thus efficacy.
- Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo
PubMed ID: 25001306
Direct randomized evidence of parasite clearance with artemisinin-based combos.
- Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria
PubMed ID: 24825870
DHA‑PPQ reduced recurrent malaria episodes and hospital stays vs comparator (clinical infection control).
- Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children
PubMed ID: 25436614
Repeated artesunate-containing treatments produced rapid parasite and gametocyte clearance.
- Longitudinal study on Plasmodium falciparum gametocyte carriage following artemether-lumefantrine administration in a cohort of children aged 12-47 months living in Western Kenya, a high transmission area
PubMed ID: 25007860
AL significantly reduced later gametocytaemia, lowering parasite transmission reservoir.
- Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children
PubMed ID: 25626448
High 42‑day PCR-corrected cure rates across ACTs indicate maintained antimalarial protection.
- Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial
PubMed ID: 26289949
Unsupervised therapy trial showing ASAQ had higher 28‑day cure than AL (real-world infection outcomes).
- Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design
PubMed ID: 25802434
Very large population MTAT reduced child parasite prevalence and case incidence — strong infection control evidence.
- Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens
PubMed ID: 25652127
Rapid parasite clearance with AL demonstrated; recurrence patterns reported.
- Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study
PubMed ID: 26511848
Both co-formulated ACTs achieved ~96–97% day-28 PCR-corrected cure—direct protective efficacy.
- Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial
PubMed ID: 26597254
ASAQ led to fewer early recurrences and superior hemoglobin recovery vs AL—enhanced short-term protection.
- Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study
PubMed ID: 25889150
Artemisinin‑NQ produced longer prophylactic window (fewer clinical episodes) than AL over 6 months.
- A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy
PubMed ID: 26169336
Both ACTs cleared parasites similarly by day 28 in pregnancy—direct antiparasitic effect.
- Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia
PubMed ID: 25985992
Large MTAT economic analysis documents cases averted — program-level infection impact.
- Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial
PubMed ID: 26578353
Seasonal chemoprevention reduced malaria incidence and parasite prevalence—prevention of parasitic episodes.
- Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study
PubMed ID: 25605477
Adherence study: better adherence to DHA‑PPQ implies greater infection treatment effectiveness (indirect).
- Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study
PubMed ID: 25881046
AL cured more children at day 28 than comparator—strong protective efficacy in pediatric population.
- Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children
PubMed ID: 26502714
Cohort documenting haematologic kinetics after ACTs; reinforces clinical course after infection treatment.
- Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial
PubMed ID: 27840069
Re‑treating with same ACT was effective for recurrent parasitaemia—supporting antiparasitic reuse.
- [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]
PubMed ID: 26644184
ACTs remained highly effective in Senegal at day 28/42 confirming protection.
- A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa
PubMed ID: 26908796
Arterolane–piperaquine demonstrated efficacy comparable to AL against P. falciparum.
- Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
PubMed ID: 26952094
Adding single low‑dose primaquine to AL almost abolished mosquito infectivity — strong infection control/transmission-blocking evidence.
- In vivo efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
PubMed ID: 27599612
Both ACTs effective in eastern DRC with AL showing slightly higher cure rates.
- Four Artemisinin-Based Treatments in African Pregnant Women with Malaria
PubMed ID: 26962727
Very large trial in pregnant women showing high PCR‑corrected cure rates across ACTs.
- Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
PubMed ID: 27471317
PK/PD in toddlers: low day‑7 lumefantrine predicted recurrence — links drug exposure to infection outcomes.
- Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania
PubMed ID: 27287612
Single low‑dose primaquine added to AL did not cause clinically important haemolysis and is safe for transmission-blocking use.
- In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014
PubMed ID: 27113085
High PCR-corrected cure and longer post-treatment protection with ASAQ vs AL—durable antiparasitic effect.
- Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial
PubMed ID: 27565897
Adding single low-dose PQ did not reduce cure rate — supports combined use for infection control.
- Can Rapid Diagnostic Testing for Malaria Increase Adherence to Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda
PubMed ID: 26928828
RDT access and adherence behavior influence whether antiparasitic treatment courses are completed.
- Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial
PubMed ID: 27430374
Artesunate–mefloquine non-inferior to AL for 63‑day PCR-corrected ACPR—durable protection evidence.
- Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial
PubMed ID: 27649561
Randomized trial showed very high cure rates for artemisinin-based ACTs in children with malaria.
- Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
PubMed ID: 27697758
PK/safety study showing tafenoquine can be coadministered with ACTs; supports combined antimalarial strategies.
- Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
PubMed ID: 28510573
Adding primaquine to schizonticidal therapy markedly reduced P. vivax relapses and recurrence over 1 year.
- Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa
PubMed ID: 29020247
Pediatric phase‑3 trial showed arterolane–piperaquine noninferior to AL with comparable safety for uncomplicated falciparum malaria.
- Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
PubMed ID: 28216244
PfSPZ vaccine provided partial protection against P. falciparum infection — direct antimalarial prevention data.
- Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria
PubMed ID: 28511713
Large randomized evaluation in pregnant women showing ACTs are effective — directly supports treating malaria infections in pregnancy.
- AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial
PubMed ID: 28916443
Phase‑2 trial showing AQ‑13 had comparable efficacy to AL in adults — supports infection treatment though sample size limited.
- Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum
PubMed ID: 28732068
Treating hypnozoites with primaquine cut relapses and gametocyte carriage — protects against recurrent malaria.
- Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
PubMed ID: 28630183
Novel lumefantrine formulations that greatly increase exposure would enhance antiparasitic activity.
- Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda
PubMed ID: 29390014
Molecular surveillance found limited immediate pfmdr1 selection after ACT retreatment; relevant to preserving efficacy against infections.
- Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial
PubMed ID: 29602751
Ivermectin regimens increased mosquito mortality and extended mosquitocidal activity — contributes to community antimalarial protection.
- A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
PubMed ID: 30290808
Randomized trial demonstrated high PCR‑corrected efficacy of DHA–piperaquine and AL; DHA‑PQ gave longer post-treatment protection.
- Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across Côte d’Ivore
PubMed ID: 29717574
Multicenter RCT found artesunate–amodiaquine and artemether–lumefantrine highly effective (~95% cure) for P. falciparum.
- Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa
PubMed ID: 33789028
Large RCT across sites showed very high PCR-corrected cure rates (~99%) for artemisinin combinations.
- Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial
PubMed ID: 35189818
Home-based pediatric treatment with ASAQ or AL produced >95% PCR-corrected cure, supporting antimalarial protection in community settings.
- Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial
PubMed ID: 36174595
Large RCT showed AL chemoprophylaxis reduced PCR-detected malaria from 17% to 3% (~85% protective efficacy) in high-risk forest goers.
- Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria
PubMed ID: 34410358
Cipargamin showed very fast parasite clearance but limited day-28 cure rates and resistance—relevant to antiparasitic development.
- Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
PubMed ID: 35276064
Adding amodiaquine to AL in areas with artemisinin resistance improved efficacy — supports treating resistant infections.
- Comparative effect of artemether-lumefantrine and artesunate-amodiaquine on gametocyte clearance in children with uncomplicated Plasmodium falciparum malaria in Madagascar
PubMed ID: 36376921
Study showed AL cleared gametocytes faster than ASAQ, implying lower post-treatment transmission potential.
- The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
PubMed ID: 36130191
Extending AL from 3 to 5 days increased drug exposure and reduced short-term recurrence risk, improving infection control.
- Efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial
PubMed ID: 37179349
Pyronaridine–artesunate (an artemisinin combination) achieved higher day‑28 PCR-corrected cure vs AL in children.
- Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial
PubMed ID: 37327809
Ganaplacide + lumefantrine showed rapid clearance and high PCR-corrected cure—strong antiparasitic evidence.
- Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
PubMed ID: 36707795
Study in people with HIV showed AL had ~94% PCR-corrected efficacy but efavirenz co-treatment lowered lumefantrine and increased risk of subtherapeutic levels.
- Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali
PubMed ID: 38705163
Direct demonstration that AL abolished transmission and tafenoquine eliminated infectivity — powerful antiparasitic/transmission evidence.
- Artemisinin combination therapy at delivery to prevent postpartum malaria: A randomised open-label controlled trial
PubMed ID: 39396742
ACT at delivery halved postpartum malaria incidence — strong antiparasitic preventive effect.
- Extension of efficacy range for targeted malaria-elimination interventions due to spillover effects
PubMed ID: 38965434
Reactive focal treatment with artemether–lumefantrine produced large reductions in malaria incidence and prevalence (spillover).
- Efficacy and gametocyte carriage in Plasmodium falciparum cases treated with artemether-lumefantrine alone versus with single-dose primaquine in Ethiopia: A randomized controlled study
PubMed ID: 40849034
Primaquine added to AL sped gametocyte elimination — transmission/protection implication though cures similar.
- Arterolane and piperaquine Vs. artemether and lumefantrine in uncomplicated malaria: A randomized study in Nigeria
PubMed ID: 41033576
Arterolane–piperaquine non‑inferior to artemether–lumefantrine for uncomplicated falciparum malaria (high efficacy).
- Efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
PubMed ID: 40845863
Multisite trial showing variable/declining AL efficacy and slower clearance with K13 mutations — relevant to antimalarial effectiveness.
- Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial
PubMed ID: 30668322
Large DRC trial: Artemisia teas cleared fever and parasites rapidly and had high microscopy cure rates.
- Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial
PubMed ID: 30466622
Artemisia annua/afra teas cleared schistosoma eggs faster and with fewer side effects than praziquantel.
- A randomized comparative study of artemisinine (qinghaosu) suppositories and oral quinine in acute falciparum malaria
PubMed ID: 2091337
Artemisinin suppositories cleared parasites and fever faster than quinine but had higher late recrudescence.
- Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria
PubMed ID: 1820641
5‑day artesunate regimens produced rapid clearance though modest 28‑day cure rates.
- Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria
PubMed ID: 1820640
7‑day artesunate produced higher cure rates than 5‑day — clinical infection benefit.
- Comparison of artemether and chloroquine for severe malaria in Gambian children
PubMed ID: 1346408
Artemether cleared parasites faster than chloroquine in Gambian children — clear antimalarial infection effect.
- Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria
PubMed ID: 1287904
Artemisinin derivatives produced much faster parasite clearance than quinine in severe/cerebral malaria — strong infection control.
- Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria
PubMed ID: 1347854
Artesunate rapidly cleared parasites and, with follow‑on mefloquine, produced complete cures in this trial.
- Artemether in the treatment of multiple drug resistant falciparum malaria
PubMed ID: 1298086
Higher dose artemether improved cure rates in 5‑day regimen — supports infection control.
- Comparison of combinations of parenteral artemisinin derivatives plus oral mefloquine with intravenous quinine plus oral tetracycline for treating cerebral malaria
PubMed ID: 1486675
Combining parenteral artemisinin derivatives with oral mefloquine markedly lowered death rates and recrudescence vs quinine regimen.
- Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria
PubMed ID: 1359318
Oral artemether cleared parasites faster and cured more patients than mefloquine in uncomplicated malaria.
- A comparative study of the schizontocidal efficacy and safety of artemether versus chloroquine in uncomplicated malaria
PubMed ID: 1477874
Artemether cleared parasites faster and had far fewer recrudescences vs chloroquine—very strong antiparasitic advantage.
- [Randomised comparison on the treatment of falciparum malaria with dihydroartemisinin and piperaquine]
PubMed ID: 8313183
Dihydroartemisinin cleared parasites and fever faster than piperaquine in falciparum malaria.
- Rapid coma resolution with artemether in Malawian children with cerebral malaria
PubMed ID: 8095573
In children with cerebral malaria artemether cleared parasites faster and led to quicker regain of consciousness.
- The efficacy of artemether in the treatment of Plasmodium falciparum malaria in Sudan
PubMed ID: 8296377
IM artemether effective and well tolerated with rapid parasitological clearance and lower recrudescence vs quinine.
- Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria
PubMed ID: 7886773
Multiple trials in Vietnam: single-dose artemisinin with mefloquine rapidly lowered parasites and reduced recrudescence in many settings—clear antiparasitic effect.
- Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria
PubMed ID: 8024075
Artesunate+doxy produced much faster fever/parasite clearance vs comparator, indicating infection control though cure rate was lower in that comparison.
- Artemisinin: large community studies
PubMed ID: 8053025
Community studies indicate artemisinin derivatives speed parasite clearance and reduce early failures when given ≥3 days.
- Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria
PubMed ID: 8067808
Pre-treatment with artesunate then mefloquine raised cure rates and cleared parasites faster vs mefloquine alone.
- Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination
PubMed ID: 7930743
Three-day artesunate+mefloquine greatly reduced treatment failures/recrudescence—direct antiparasitic efficacy against Plasmodium.
- Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria
PubMed ID: 8205643
Oral artesunate gave much faster parasite clearance vs quinine+tetracycline—antiparasitic effect.
- Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria
PubMed ID: 8036679
Single-day artesunate plus mefloquine prevented early failures and improved parasitological response speed.
- Tolerability and pharmacokinetics of Ro 42-1611 (arteflene) in man
PubMed ID: 7899804
Arteflene (not artemisinin) showed ex vivo P. falciparum inhibition in healthy volunteers at higher doses—suggests antiplasmodial activity but different compound and early-phase data.
- Artemether-mefloquine combination in multidrug resistant falciparum malaria
PubMed ID: 7778152
Single-dose artemether improved cure rates and rapidly cleared parasites when combined with mefloquine.
- Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine
PubMed ID: 8561267
Oral and IV artesunate gave comparable rapid parasite and fever clearance—demonstrates effective infection treatment.
- Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria
PubMed ID: 8560531
Large RCT: artemisinin derivatives with mefloquine cut reinfection-adjusted failure rates substantially—strong antiparasitic evidence.
- Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand
PubMed ID: 8594692
Intramuscular artemether in severe malaria improved survival and accelerated parasite clearance—direct antiparasitic benefit.
- Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria
PubMed ID: 7485711
Randomized trial showing much faster parasite/febrile clearance and higher cure with artesunate vs quinine.
- A comparative clinical trial of artemether and the sequential regimen of artemether-mefloquine in multidrug resistant falciparum malaria
PubMed ID: 8821610
Both regimens rapidly cleared parasites; combination slightly improved fever resolution and cure rates—modest antimalarial advantage.
- A comparative clinical trial of two different regimens of artemether plus mefloquine in multidrug resistant falciparum malaria
PubMed ID: 7660440
Higher mefloquine dose with artemether gave better cure rates and fast clearance—supports improved infection outcomes.
- [Field studies on preventive effect of artemether against infection with Schistosoma japonicum]
PubMed ID: 8556789
Large preventive artemether trial lowered schistosomiasis infection rates and egg counts—direct antiparasitic evidence (non-malarial parasite).
- Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria
PubMed ID: 8799526
Adding mefloquine to artemisinin increased exposure and sped parasite/fever clearance vs monotherapy—enhanced anti-infective effect.
- Effects of artemisinin derivatives on malaria transmissibility
PubMed ID: 8642959
Programmatic use of artemisinin derivatives markedly reduced gametocyte carriage and malaria incidence—strong antiparasitic, population-level effect.
- Artemether or artesunate followed by mefloquine as a possible treatment for multidrug resistant falciparum malaria
PubMed ID: 8882193
Single-dose artemether/artesunate followed by mefloquine produced very rapid clearance and very high cure rates—strong anti-infective finding.
- Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients
PubMed ID: 8730315
Artesunate worked faster than artemisinin and shortened parasite/fever clearance times—supports control of infection though PK autoinduction noted.
- Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil
PubMed ID: 8619447
Artesunate+tetracycline markedly increased day-2 parasite clearance (large RCT).
- Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria
PubMed ID: 9031394
Short artemether–pyrimethamine regimens cleared parasites quickly; only 3‑day schedule had acceptable cure rates in resistant malaria.
- A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
PubMed ID: 8649493
Artemether cleared parasites faster and had trend to lower deaths vs quinine in severe malaria—supports infection treatment.
- Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria
PubMed ID: 8916803
Adding one dose of artemisinin sped parasite clearance though some short regimens had high relapse rates—acute infection control but relapse risk.
- In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria
PubMed ID: 8791866
Qinghaosu (artemisinin) very effective vs chloroquine/SP with very low failure rate—antiparasitic efficacy demonstrated.
- A trial of artemether or quinine in children with cerebral malaria
PubMed ID: 8649492
Cerebral malaria trial showing therapeutic antiparasitic activity (rapid parasite clearance) → supports antiparasitic action.
- [An efficacy and tolerance study of oral artesunate alone and in combination with mefloquine in the treatment of uncomplicated falciparum malaria in an endemic area of Pará, Brazil]
PubMed ID: 8701045
Artesunate-containing regimens cleared parasites and fever faster than comparators → strong antimalarial/infectious disease effect.
- Open comparison of artemether and mefloquine in uncomplicated Plasmodium falciparum hyperparasitaemia in children
PubMed ID: 8787366
Markedly faster parasite reduction vs mefloquine → strong antiparasitic evidence.
- An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children
PubMed ID: 8758084
Rapid parasite clearance in severe malaria → supports antiparasitic activity.
- Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria
PubMed ID: 9231212
Artemisinin suppositories/artesunate cleared parasites faster than quinine in severe childhood malaria with acceptable tolerability.
- Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria
PubMed ID: 9196767
Single-dose artemisinin + mefloquine improved cure and reduced recrudescence → strong antiparasitic evidence.
- Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria
PubMed ID: 9230790
Longer artemether courses or sequential mefloquine improved cure rates markedly.
- A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand
PubMed ID: 9561593
Short-course artemisinin + mefloquine regimens were highly effective against multidrug‑resistant falciparum malaria.
- Severe and complicated malaria treated with artemisinin, artesunate or artemether in Viet Nam
PubMed ID: 9373657
Multiple artemisinin formulations gave rapid parasite clearance in severe malaria.
- Effect of artemether on electrocardiogram in severe falciparum malaria
PubMed ID: 9561594
Artemether efficacy seen with acceptable tolerability vs quinine; supports antimalarial use though focus was cardiac safety.
- A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand
PubMed ID: 9311648
Higher‑dose artesunate followed by mefloquine cleared parasites faster and improved cure rates vs lower dose.
- Two doses of artemether/mefloquine or artesunate/mefloquine combination for multidrug resistant falciparum Malaria
PubMed ID: 9656393
Two-dose combinations achieved complete cure and rapid clearance → very strong antiparasitic evidence.
- Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5- and 7-day regimens
PubMed ID: 9241384
5–7 day artesunate regimens cured nearly all uncomplicated falciparum malaria → strong antiparasitic support.
- [The evaluation of the efficacy of artesunate combined with tetracycline in the therapy of falciparum malaria]
PubMed ID: 9273568
Artesunate cleared parasites faster than quinine or mefloquine in a small trial.
- [Comparison on treatment of falciparum malaria with different courses of artesunate tablet]
PubMed ID: 9863077
Longer artesunate courses markedly reduced recrudescence compared with 3‑day course.
- Preventive effect of artemether on schistosome infection
PubMed ID: 10374370
Large randomized field study showing artemether dramatically reduced schistosome infections and prevented acute disease → very strong antiparasitic preventive effect.
- Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria
PubMed ID: 9764335
Adding mefloquine to artesunate substantially reduced recurrence → strong combination antiparasitic evidence.
- Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria
PubMed ID: 9886194
Both artesunate and artemether rapidly cleared parasites with low recurrence → robust antiparasitic support.
- Intramuscular artemether vs intravenous quinine: an open, randomized trial in Malawian children with cerebral malaria
PubMed ID: 9484961
Artemether cleared parasites faster than quinine in cerebral malaria — direct antiparasitic effect.
- Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria
PubMed ID: 9452284
Artesunate suppositories achieved similar 28‑day cure despite slower initial parasite reduction — supports antiparasitic activity.
- Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand
PubMed ID: 9763724
Short-course artesunate improved cure rates and adherence compared with quinine regimen — strong antimalarial benefit.
- Randomized comparison of intramuscular artemether and intravenous quinine in adult, Melanesian patients with severe or complicated, Plasmodium falciparum malaria in Papua New Guinea
PubMed ID: 9625908
Faster parasite clearance than quinine in severe malaria — clear antiparasitic benefit.
- Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar
PubMed ID: 9763721
Blister packaging improved adherence and thus antiparasitic treatment delivery; adding mefloquine gave marginal extra effect.
- Comparison of rectal artemisinin with intravenous quinine in the treatment of severe malaria in Ethiopia
PubMed ID: 10442116
Rectal artemisinin cleared parasites faster than quinine — supports antiparasitic action.
- [Comparative study of artemether and quinine in severe Plasmodium falciparum malaria in adults and older children in Cameroon]
PubMed ID: 10546188
Artemether achieved better overall parasite clearance than quinine in Cameroon.
- A randomized safety and tolerability trial of artesunate plus sulfadoxine--pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children
PubMed ID: 10696418
Adding short-course artesunate to SP sped parasite clearance and lowered gametocyte carriage.
- Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand
PubMed ID: 10674681
Artesunate+primaquine regimens achieved 100% day‑28 cures in P. vivax — very strong antiparasitic evidence.
- Cost-effectiveness analysis of artesunate and quinine + tetracycline for the treatment of uncomplicated falciparum malaria in Chanthaburi, Thailand
PubMed ID: 10212514
Oral artesunate cured all patients in trial — excellent antiparasitic result.
- Comparative clinical trial of four regimens of dihydroartemisinin-mefloquine in multidrug-resistant falciparum malaria
PubMed ID: 10540300
DHA+high‑dose mefloquine resulted in far fewer recrudescences — supports strong antimalarial protection when used appropriately.
- Comparative efficacy of intramuscular artemether and intravenous quinine in Nigerian children with cerebral malaria
PubMed ID: 10546840
In cerebral malaria, intramuscular artemether produced rapid parasite and fever clearance comparable to IV quinine.
- Efficacy and effectiveness of five day treatment of uncomplicated falciparum with artemisinin or artesunate in Vietnam
PubMed ID: 10695777
Supervised 5‑day artemisinin regimens yielded 100% cure in efficacy assessments.
- Dose findings of dihydroartemisinin in treatment of falciparum malaria
PubMed ID: 10695780
Higher total dose/longer DHA produced far fewer recrudescences—dose‑dependent antiparasitic effect.
- [Rapid resolution of Plasmodium ovale malarial attacks using artesunate (Arsumax)]
PubMed ID: 10472581
Artesunate rapidly cleared P. ovale infections.
- Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics
PubMed ID: 10770766
Combination artemisinin+quinine accelerated parasite elimination vs quinine alone, reducing infection burden.
- A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand
PubMed ID: 11414432
Artesunate+mefloquine had very high cure rates vs artesunate alone.
- A randomized controlled trial of artemotil (beta-arteether) in Zambian children with cerebral malaria
PubMed ID: 11220772
Large pediatric RCT showed intramuscular artemotil as effective and safe as IV quinine for cerebral malaria — strong anti-infective evidence.
- Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial
PubMed ID: 10776745
Large RCT in schoolchildren showed ~50% reduction in new S. mansoni infections and lower egg counts — strong antiparasitic evidence.
- Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial
PubMed ID: 10665554
Adding artesunate sped parasite clearance and reduced gametocytes in 600 children — clear clinical infection benefit.
- Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy
PubMed ID: 11198658
Pregnant-women trial: artesunate+mefloquine produced much higher day-63 cure rates and far fewer gametocytes than quinine — strong infection control.
- Rectal dihydroartemisinin versus intravenous quinine in the treatment of severe malaria: a randomised clinical trial
PubMed ID: 12858920
Rectal dihydroartemisinin cleared parasites faster with fewer side effects than IV quinine in severe malaria.
- Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria pregnant women
PubMed ID: 11800303
In pregnancy artesunate+mefloquine cleared parasites/fever faster and preserved hematocrit better than quinine — robust anti-infective outcome.
- Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study
PubMed ID: 11679932
Artesunate+praziquantel produced high cure rates for S. haematobium; artesunate alone had low cure — substantial combination antiparasitic effect.
- Clinical trial of beta-arteether versus quinine for the treatment of cerebral malaria in children in Yaounde, Cameroon
PubMed ID: 11463108
Arteether had similar recovery and slightly lower (non-significant) mortality than quinine in pediatric cerebral malaria — modest evidence.
- Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy?
PubMed ID: 11791958
Artemisinin monotherapy cleared parasites rapidly but relapsed commonly → strong immediate effect but limited durable protection as monotherapy.
- Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria
PubMed ID: 11120963
IV artesunate rapidly converts to active DHA and clears parasites quickly and safely in severe falciparum malaria.
- Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro
PubMed ID: 11491008
Artesunate cleared parasites rapidly in the field study but showed notable recrudescence — antiparasitic effect tempered by recurrence.
- Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy
PubMed ID: 11816439
Seven-day artesunate cured all pregnant patients and reduced gametocyte weeks dramatically vs quinine/clindamycin.
- Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia
PubMed ID: 11693875
Artesunate+SP reduced short-term treatment failure and gametocyte carriage compared with SP alone — clear antiparasitic benefit.
- [A study of artemether combined with primaquine in the treatment of falciparum malaria]
PubMed ID: 12572052
Artemether+primaquine lowered relapse rates vs artemether alone — meaningful reduction in recurrent infection.
- Artemether vs quinine therapy in Plasmodium falciparum malaria in Manipur--a preliminary report
PubMed ID: 12170942
Artemether cleared parasites faster and had fewer deaths vs quinine—strong antiparasitic clinical evidence.
- Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria
PubMed ID: 12185558
PK/PD modelling showed time>MIC short and dose/time-dependent parasite clearance—supports antiparasitic dosing strategy.
- Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens
PubMed ID: 11897585
Consistent dosing (500 mg/day) produced higher exposure and faster parasite clearance vs escalating dosing—antimalarial dosing evidence.
- Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial
PubMed ID: 11978332
Multicenter trial in African children: adding artesunate improved cure rates substantially at key sites (strong protection against malaria).
- Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand
PubMed ID: 12479545
Randomized study: 3‑day simultaneous artesunate+mefloquine produced high cure rates comparable to standard dosing (infection control/equivalence).
- Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam
PubMed ID: 12358621
Artemisinin and chloroquine cleared P. vivax equally fast, but short-course artemisinin did not prevent relapse—mixed antiparasitic evidence.
- Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria
PubMed ID: 11994055
Artemotil absorption slower than artemether leading to later clearance—pharmacologic antiparasitic implication.
- Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil
PubMed ID: 12471569
Large randomized trial showing inclusion of artesunate produced markedly faster clearance, far fewer failures and much lower gametocyte carriage (high‑certainty antimalarial benefit).
- Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial
PubMed ID: 12504399
Randomized pediatric study: SP+artesunate sharply reduced early treatment failures and subsequent episodes (clear antimalarial protection).
- A randomized, double-blind study on the efficacy and safety of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa
PubMed ID: 12625145
3‑day co-administered artesunate+mefloquine highly effective with excellent cure rates—practical antimalarial protection.
- Oral artesunate dose-response relationship in acute falciparum malaria
PubMed ID: 11850261
Dose–response study defined ED50 and showed substantial parasite clearance shortening—direct antimalarial pharmacodynamics.
- The efficacy of artemether versus quinine in the treatment of cerebral malaria
PubMed ID: 12214938
Randomized comparison in children: artemether produced modestly faster clinical/parasitological recovery vs quinine.
- Comparison of intramuscular artemether and intravenous quinine in the treatment of Sudanese children with severe falciparum malaria
PubMed ID: 12683344
Small trial: intramuscular artemether cleared parasites and coma faster than quinine (clinical antimalarial benefit).
- An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand
PubMed ID: 12693586
Large trial showing ≈97% 28‑day cure with Artecom (antimalarial efficacy comparable to standard regimens).
- Efficacy of artesunate plus chloroquine for uncomplicated malaria in children in Sao Tome and Principe: a double-blind, randomized, controlled trial
PubMed ID: 16117967
Large pediatric RCT: adding artesunate to chloroquine greatly reduced parasitaemia and failure rates (strong antimalarial protection).
- Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial
PubMed ID: 15228253
420‑child trial: 3 days artesunate+SP markedly increased cure rates and reduced gametocytes vs SP alone.
- Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria
PubMed ID: 12830403
Artesunate reduced parasite clearance time and hypoglycaemia vs quinine in adults with severe malaria.
- Efficacy of artesunate plus chloroquine for the treatment of uncomplicated malaria in children in Burkina Faso: a double-blind, randomized, controlled trial
PubMed ID: 15228257
300‑child RCT: CQ+AS markedly improved day14/day28 parasite outcomes vs CQ alone.
- Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections
PubMed ID: 12556143
Large RCT: intermittent artemether significantly reduced S. haematobium incidence and egg burden in children (strong antiparasitic evidence).
- Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial
PubMed ID: 15307433
Strong RCT evidence of reduced parasitological failure and faster clearance when artesunate added.
- [A randomized comparative study of naphtoquine, mefloquine and artsunate in the treatment of falciparum malaria]
PubMed ID: 14521743
Rapid parasite clearance documented though 28-day cure was lower than comparator.
- Therapeutic equivalence of a low dose artemisinin formulation in falciparum malaria patients
PubMed ID: 12631411
Lower-dose cyclodextrin formulation performed equivalently for parasite cure/clearance.
- A comparative clinical trial of artemether and quinine in children with severe malaria
PubMed ID: 14581730
Faster parasite clearance in severe malaria vs quinine.
- Randomised efficacy and safety study of two 3-day artesunate rectal capsule/mefloquine regimens versus artesunate alone for uncomplicated malaria in Ecuadorian children
PubMed ID: 14636982
Combination therapy greatly increased 28-day cure rates and reduced relapse vs monotherapy.
- Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand
PubMed ID: 12932090
Rapid clearance of P. vivax blood stages but relapse common without primaquine.
- The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure
PubMed ID: 12932091
Significant reduction in parasitaemia during follow-up when artesunate added to chloroquine.
- Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru
PubMed ID: 12812355
Mefloquine-artesunate produced faster asexual parasite decline and lower gametocyte prevalence.
- Lack of prediction of mefloquine and mefloquine-artesunate treatment outcome by mutations in the Plasmodium falciparum multidrug resistance 1 (pfmdr1) gene for P. falciparum malaria in Peru
PubMed ID: 12557835
High 28-day efficacy of mefloquine and mefloquine-artesunate reported.
- Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate?
PubMed ID: 14614668
Regional variability in in vivo cure rates demonstrates context-dependent antiparasitic effect.
Wellbeing (131)
- Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania
PubMed ID: 19352498
Pregnancy trial: improved parasitological outcomes and lower gametocyte carriage with AQ+AS likely translate to better maternal health outcomes in context of malaria treatment.
- Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
PubMed ID: 29764419
High cure rates and lack of liver toxicity support safe, effective treatment contributing to wellness.
- Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
PubMed ID: 29606364
Longitudinal effectiveness for repeated treatment supports continued population‑level wellness in endemic areas.
- Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial
PubMed ID: 33983371
High cure rates and rapid clearance in asymptomatic carriers support improved health outcomes at community level.
- A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India
PubMed ID: 11037786
Large trial with dramatic improvement in cure rates and symptom resolution—strong contribution to patient wellbeing.
- Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh
PubMed ID: 16095643
Superior effectiveness of ACTs over failing regimens and prevention of gametocytes support public‑health wellness gains.
- Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial
PubMed ID: 15850631
Marked reductions in treatment failure and recrudescence in children indicate large public‑health wellness benefits.
- Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial
PubMed ID: 15850630
High cure rates and routine practice effectiveness imply improved clinical wellness in treated populations.
- Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults
PubMed ID: 16923176
Fewer treatment failures and better hemoglobin recovery indicate improved overall clinical outcomes.
- Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial
PubMed ID: 17519410
Community trial showed reduced anemia and parasitemia, implying broad wellness benefits at population level.
- Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal
PubMed ID: 17570848
Artemisinin combinations rapidly resolve infection and gametocytemia, supporting community health/wellness.
- Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania
PubMed ID: 17996121
Complete parasitological cure and haemoglobin recovery support improved overall health in children.
- Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
PubMed ID: 18796142
Demonstrated lack of persistent ototoxicity for AL—supports overall treatment safety and wellbeing.
- Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial
PubMed ID: 18926569
Pediatric dispersible formulation effective and safe—improves practical wellness and treatment adherence.
- Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial
PubMed ID: 18606428
High real-world effectiveness and adherence with AL supports practical improvement in health and wellness.
- Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial
PubMed ID: 19366448
Multicentre non-inferiority with high cure rates and acceptable tolerability supports population wellness.
- A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops
PubMed ID: 20594372
Increased availability/uptake of ACTs through subsidy can enhance community health, though uneven reach limits impact.
- Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children
PubMed ID: 20689585
Sustained ACT efficacy associated with declines in malaria incidence and anemia across 4 years, supporting community wellness.
- Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia
PubMed ID: 21666744
Lower failure rates and less early anemia with AL vs comparator supports better clinical wellbeing.
- Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial
PubMed ID: 22166001
Combined IPTc+HMM markedly reduced malaria incidence and anemia, producing substantial population-level wellness gains for children.
- The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
PubMed ID: 21655317
Retail subsidy and training doubled timely AL use in young children, improving timely care and likely wellbeing.
- Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4-59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial
PubMed ID: 22172305
Monthly AL after discharge reduced deaths/readmissions—improves post-severe-malaria outcomes and child wellness.
- A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial
PubMed ID: 22087077
Large trials show effective treatment of malaria with improved outcomes — contributes to population-level wellness via disease control.
- Comparative feasibility of implementing rapid diagnostic test and microscopy for parasitological diagnosis of malaria in Uganda
PubMed ID: 22182758
Using RDTs increased testing and reduced unnecessary AL prescriptions, improving quality of care and efficiency.
- Quality and safety of integrated community case management of malaria using rapid diagnostic tests and pneumonia by community health workers
PubMed ID: 22595272
Community implementation enabling correct treatment contributes to overall health/wellness in rural settings.
- A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso
PubMed ID: 23442748
Large cluster trial reduced parasitaemia and improved Hb short-term—some benefits to overall child health though symptomatic incidence unchanged.
- An open randomized controlled trial to compare the efficacy of two fixed dose combinations of artemesinin based combinations for uncomplicated falciparum malaria in Bangladesh
PubMed ID: 26118157
Open randomized trial showing high cure rates and good tolerability supports treatment‑related wellness.
- Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
PubMed ID: 23866736
Large safety trial showing both ACTs generally safe but some increased fatigue/vomiting with ASAQ—relevant to tolerability/wellness.
- Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial
PubMed ID: 23866774
Both ACTs cured reliably with AL giving slightly longer protection—overall clinical tolerability contributes to wellness.
- Efficacy of artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children
PubMed ID: 24334945
High cure rates and good safety in Nigerian children indicate favorable overall clinical outcomes.
- Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children
PubMed ID: 25246693
Large multi‑site trial showing rapid parasite/fever clearance and reduced gametocyte carriage — supports recovery/wellness.
- Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire
PubMed ID: 25409546
Maintained high efficacy and safety through 42 days supports clinical well‑being after treatment.
- Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria
PubMed ID: 24825870
DHA‑PPQ reduced hospitalizations and malaria episodes in children — improved clinical welfare.
- Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design
PubMed ID: 25802434
Large MTAT reduced child parasite prevalence and outpatient malaria incidence — program-level wellness gains.
- Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens
PubMed ID: 25652127
Rapid parasite clearance but frequent recurrences; chemoprevention improved outcomes — programmatic wellness implications.
- Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial
PubMed ID: 26597254
Fewer recurrences and better hemoglobin recovery after ASAQ indicate improved clinical recovery and wellbeing.
- Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia
PubMed ID: 25985992
Economic analysis shows MTAT averted many cases and DALYs — supports overall public-health benefit.
- Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial
PubMed ID: 26578353
SMC reduced malaria cases and prevalence during rainy season — child health/wellness impact.
- Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial
PubMed ID: 27840069
Retreatment strategies with ACTs gave similar efficacy and better tolerability — supports patient wellbeing.
- Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
PubMed ID: 26952094
Markedly shortened gametocyte carriage and abolished most post-treatment infectivity—reduces transmission burden and community wellness.
- Four Artemisinin-Based Treatments in African Pregnant Women with Malaria
PubMed ID: 26962727
Pregnancy trial showing effective, generally safe ACTs and no adverse birth outcomes — maternal/infant wellness.
- Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial
PubMed ID: 27430374
Large pediatric non-inferiority trial with sustained cure and tolerability — supports child health outcomes.
- Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial
PubMed ID: 36174595
Chemoprophylaxis substantially reduced infections in high-risk workers, likely improving overall health and functioning.
- Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial
PubMed ID: 30466622
Faster schistosome egg elimination and fewer adverse effects with Artemisia teas vs praziquantel suggests better tolerability and symptom resolution.
- Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria
PubMed ID: 1359318
Oral artemether had fewer side effects than mefloquine along with faster recovery—positive overall wellness signals.
- Artemisinin: large community studies
PubMed ID: 8053025
Community studies: faster recovery and fewer early failures when artemisinin derivatives given ≥3 days → supports wellness improvements.
- Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination
PubMed ID: 7930743
Three-day artesunate+mefloquine greatly reduced treatment failures and accelerated recovery—clinical outcomes that support patient-level wellness.
- Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria
PubMed ID: 8560531
Large trial showing major reductions in failure rates and faster recovery when artemisinin derivatives are used—supports improved clinical outcomes.
- Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand
PubMed ID: 8594692
Improved survival in severe malaria with artemether suggests meaningful contribution to overall patient wellbeing in high-risk cases.
- Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria
PubMed ID: 7485711
Faster fever and parasite clearance and higher cure rates translate to improved clinical outcomes and wellbeing.
- Effects of artemisinin derivatives on malaria transmissibility
PubMed ID: 8642959
Programmatic introduction of artemisinin derivatives correlated with a ~47% drop in malaria incidence—population-level benefit that may improve community wellness.
- Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria
PubMed ID: 9196767
Improved cure rates and reduced relapses with artemisinin combinations contribute to better health outcomes overall.
- A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand
PubMed ID: 9561593
High cure rates and good tolerability for short-course combination regimens contribute to community-level wellness by controlling malaria.
- Preventive effect of artemether on schistosome infection
PubMed ID: 10374370
Preventing schistosomiasis infection and acute disease in exposed populations has clear positive effects on overall health/wellness.
- Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria
PubMed ID: 9886194
Rapid clearance and low recurrence support better short-term health/wellness in treated patients.
- Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand
PubMed ID: 9763724
Higher cure rates and better adherence contribute to better individual outcomes and overall wellness.
- Cost-effectiveness analysis of artesunate and quinine + tetracycline for the treatment of uncomplicated falciparum malaria in Chanthaburi, Thailand
PubMed ID: 10212514
100% cure and cost-effectiveness in trial imply programmatic wellness benefits.
- Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil
PubMed ID: 12471569
Large trial: adding artesunate reduced failures, sped recovery and reduced transmission—broad public‑health and patient‑wellness implications.
- Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial
PubMed ID: 12504399
Addition of artesunate to SP in children sharply reduced early failures and repeat episodes—practical wellness benefit in treated children.
- Efficacy of artesunate plus chloroquine for uncomplicated malaria in children in Sao Tome and Principe: a double-blind, randomized, controlled trial
PubMed ID: 16117967
Large pediatric trial: marked reductions in parasitaemia and failures when artesunate added—improves child health/wellness at population level.
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
PubMed ID: 16125588
Mortality reduction in severe malaria is a major contribution to overall health and wellbeing.
- Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial
PubMed ID: 16503464
Seasonal IPT with artesunate+SP markedly reduced malaria episodes in children, which would substantially improve overall child health and wellbeing.
- Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar
PubMed ID: 17519010
Higher cure rates, faster parasite clearance and reduced gametocytes in children imply substantial clinical benefit and improved well-being.
- Artesunate, artemether or quinine in severe Plasmodium falciparum malaria?
PubMed ID: 17402835
Mortality reduction in severe malaria with artesunate implies major overall health benefit for affected patients.
- A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru
PubMed ID: 17971864
Faster parasite clearance and fewer adverse effects with DHA–piperaquine can improve recovery experience (wellness).
- Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children
PubMed ID: 17325222
Faster parasite clearance and lower gametocyte carriage in children translate into quicker clinical recovery and reduced transmission burden.
- Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa
PubMed ID: 18154655
Community trial showing large reductions in failure and faster clinical recovery supports population-level wellness gains.
- Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria
PubMed ID: 17366451
Fewer recurrent infections and better hematologic recovery with DHA–piperaquine implies better patient outcomes and recovery.
- A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia
PubMed ID: 17300633
High cure rates with better tolerability for DHA–piperaquine imply positive impact on patient well-being.
- Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria
PubMed ID: 18838149
Higher cure rates and reduced urinary blood/protein in schistosomiasis would contribute to better wellbeing post‑treatment.
- Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial
PubMed ID: 19098989
Monthly AS+AQ reduced malaria episodes and anaemia in children which would improve overall child health/wellness during the intervention.
- Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
PubMed ID: 19059639
Pre‑referral artesunate reduced death/permanent disability in severe malaria when referral delayed — major overall health benefit in that setting.
- Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria
PubMed ID: 18343702
High cure rates with a simplified regimen imply pragmatic benefits for patient wellbeing and adherence.
- Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial
PubMed ID: 19558654
Improved cure rates and faster parasite clearance when adding artesunate to SP supports better clinical recovery and wellness.
- Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
PubMed ID: 19698172
Pooled data: AS&AQ's high efficacy and reduced gametocyte carriage imply broader community‑health/wellness gains.
- Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali
PubMed ID: 19497079
IPT with artesunate‑containing regimens reduced clinical malaria, asymptomatic parasitaemia and improved mean haemoglobin in schoolchildren — meaningful public‑health wellness benefit.
- The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria
PubMed ID: 19725966
Children treated with artesunate showed behavioral/tone improvements as illness resolved — supports clinical recovery/wellness during convalescence.
- Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali
PubMed ID: 19128455
Faster parasite clearance and PCR‑corrected cures in children support improved recovery and wellness.
- Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa
PubMed ID: 19257898
SP+AS dramatically lowered long‑term clinical failure rates — strong contribution to population health and wellness.
- Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon
PubMed ID: 20170477
Programmatic multi‑site data showing rapid parasite clearance and high cure rates across Cameroon — supports overall malaria‑related wellness.
- Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial
PubMed ID: 20368815
IPTi with artemisinin-containing regimens reduced clinical malaria and some anaemia in infants—contributes to overall child health.
- Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children
PubMed ID: 20808923
Monthly seasonal IPTc with AS+AQ reduced malaria incidence by ~69% and anaemia by 45%—substantial public-health benefit likely to promote child wellness.
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
PubMed ID: 21062666
Reduction in severe malaria mortality and complications with parenteral artesunate supports improved health outcomes and wellness in hospitalized children.
- Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea
PubMed ID: 21379417
ACTs improved clinical outcomes in children and were cost-effective, supporting broader wellness benefits in endemic settings.
- Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria
PubMed ID: 22252804
Large prevention trial showing nearly complete protection from malaria over months would substantially improve community health and wellbeing.
- Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana
PubMed ID: 23136273
Community treatment reduced child mortality — major contribution to overall community wellness.
- Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance
PubMed ID: 24354627
Two‑year surveillance: ACTs were effective and well tolerated with rapid clearance — contributes to community health and wellness.
- High adherence to antimalarials and antibiotics under integrated community case management of illness in children less than five years in eastern Uganda
PubMed ID: 23555980
CHW delivery of AL achieved high adherence — better treatment delivery supports population wellness.
- Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial
PubMed ID: 25493596
Monthly DP lowered malaria incidence and asymptomatic parasitaemia in HIV‑exposed infants — likely improves wellbeing.
- Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial
PubMed ID: 25093754
Monthly DP reduced malaria, silent infections and anemia in young children → broader wellness gains.
- Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial
PubMed ID: 24621953
Monthly DP markedly reduced malaria and anemia in schoolchildren — large public‑health benefit likely improving overall wellness.
- Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial
PubMed ID: 26429700
Reduced maternal malaria and anaemia during pregnancy improves maternal–fetal health and overall wellness.
- Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy
PubMed ID: 26962728
Monthly DP in pregnancy markedly reduced infections and associated adverse outcomes — improves maternal/neonatal wellness.
- Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial
PubMed ID: 26921676
Reduced schistosomiasis reinfection in children supports better health and school attendance—overall wellness benefit.
- Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial
PubMed ID: 27923947
MDA substantially reduced malaria burden at a population level, contributing to community health/wellness.
- Malaria illness mediated by anaemia lessens cognitive development in younger Ugandan children
PubMed ID: 27076184
Preventing malaria in young children reduced illness and anemia and was linked to better cognitive outcomes — broader wellness benefit.
- Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10
PubMed ID: 27067196
Chemoprevention reduced episodes and favored protective T‑cell responses — clinical and immunologic wellness indicators.
- Economic evaluation of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital-Cameroon: a cost analysis
PubMed ID: 27923381
Shorter hospital stays and better parasite clearance with artesunate imply faster recovery and patient wellbeing.
- Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial
PubMed ID: 28108368
SP+PQ IPT in schoolchildren reduced anaemia and clinical malaria, improving health/wellness outcomes over 12 months.
- Expanding access to parasite-based malaria diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment
PubMed ID: 28049481
Increasing diagnostic uptake and appropriate treatment in retail outlets can improve health outcomes/population wellness.
- Use of malaria rapid diagnostic tests by community health workers in Afghanistan: cluster randomised trial
PubMed ID: 28683750
CHW testing improved appropriate treatment substantially — operational benefit to community wellness despite more antibiotic use.
- Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya
PubMed ID: 30016316
Community testing plus voucher improved targeting of ACT subsidies and testing uptake — supports better health outcomes/community wellness.
- A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages
PubMed ID: 29522113
MDA with DHA–piperaquine produced dramatic short-term reductions in falciparum cases — population-level wellness improvement.
- Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial
PubMed ID: 29866192
AL had higher measured adherence and fewer side effects than AQAS—improves real‑world treatment outcomes and wellbeing.
- The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos
PubMed ID: 30390647
Large community MDA sharply reduced asymptomatic reservoirs, implying improved population health/wellness.
- Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria
PubMed ID: 29976228
ISTp with AL non‑inferior to IPTp‑SP for severe maternal anaemia and lowered parasitaemia—benefit to maternal health.
- A Competing-Risk Approach for Modeling Length of Stay in Severe Malaria Patients in South-East Asia and the Implications for Planning of Hospital Services
PubMed ID: 29562258
Artesunate lowered deaths and increased probability of discharge in severe malaria—meaningful overall health improvement.
- Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial
PubMed ID: 31353217
Monthly DP in pregnancy reduced malaria at delivery and clinical malaria—beneficial for maternal and fetal health.
- Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial
PubMed ID: 31307883
Monthly DP nearly eliminated malaria in children while given—clear benefit to child health and wellbeing.
- Intermittent preventive treatment of malaria delivered to primary schoolchildren provided effective individual protection in Jinja, Uganda: secondary outcomes of a cluster-randomized trial (START-IPT)
PubMed ID: 31533845
School IPT markedly reduced infections and symptomatic malaria—large wellness benefit for students.
- The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial
PubMed ID: 30768615
Targeted DP MDA produced rapid falls in malaria that likely improved community‑level wellness.
- Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial
PubMed ID: 30865632
Large reductions in malaria incidence and improved hemoglobin in children imply significant population health/wellness gains.
- Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children
PubMed ID: 30418593
Superior performance of DHA‑PQ vs AL at preventing recurrent malaria improves individual and community wellbeing.
- Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal
PubMed ID: 32483161
ACTs remained highly effective in Senegal with rapid clearance and no resistance markers — supports continued population health.
- Cost-Effectiveness of Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine for Malaria Prevention in Southern Province, Zambia: Results of a Community-Randomized Controlled Trial
PubMed ID: 32618249
MDA averted infections/cases and was cost‑effective in higher transmission areas — supports broader public health/wellness.
- Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
PubMed ID: 32171078
TACTs restored cure in resistant settings, improving community treatment success and overall health.
- Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial
PubMed ID: 32334702
Combined reactive focal MDA and vector control produced large incidence and prevalence reductions — clear community wellness benefit.
- Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and Plasmodium falciparum Clearance in Southern Province, Zambia
PubMed ID: 32618267
Operational MDA showed high adherence and effective parasite clearance — supports programmatic wellness outcomes.
- Malaria Chemoprevention in the Postdischarge Management of Severe Anemia
PubMed ID: 33264546
Monthly DP after severe anemia substantially reduced readmission or death — strong individual and population wellness impact.
- Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia
PubMed ID: 32618247
Large declines in malaria burden at population level likely support community wellness and reduced disease burden.
- Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial
PubMed ID: 33891721
Monthly DP during pregnancy reduced placental malaria and low birthweight, improving maternal/newborn health outcomes (wellness).
- Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial
PubMed ID: 34147154
MDA produced large reductions in falciparum prevalence in hotspots—likely improves community health/wellness short term.
- Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial
PubMed ID: 38224710
Reducing maternal malaria and placental infection contributes to maternal/infant health outcomes (overall wellness).
- Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali
PubMed ID: 37682871
Monthly DHA‑PQ reduced clinical malaria and improved hemoglobin/gametocyte outcomes in schoolchildren — tangible population wellness benefits.
- Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial
PubMed ID: 39718172
Weekly DP reduced malaria hospitalisations and transfusions in sickle cell children — improved clinical outcomes and likely wellbeing.
- Dihydroartemisinin-piperaquine effectiveness for seasonal malaria chemoprevention in settings with extended seasonal malaria transmission in Tanzania
PubMed ID: 38273019
Operational SMC with DHA‑PPQ lowered malaria prevalence and anemia, supporting community wellness.
- Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda
PubMed ID: 40966190
DP prevented malaria in pregnancy (wellness) but had adverse birthweight signals reducing net wellness benefit.
- Targeting malaria in high-risk populations in low endemic regions in northern Namibia: a quasi-experimental controlled trial to reduce malaria in seasonal agricultural workers and cattle herders
PubMed ID: 39961693
Worksite interventions increased coverage and reduced malaria prevalence in high‑risk seasonal workers (wellness impact).
- Effectiveness of sulfadoxine-pyrimethamine plus amodiaquine and dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial
PubMed ID: 39826559
Large reductions in malaria incidence and anemia in children contribute strongly to population wellness.
- Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial
PubMed ID: 39799956
MDA produced pronounced short‑term public‑health benefits improving community wellbeing transiently.
- Efficacy and Safety of Artesunate + Amodiaquine and Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Madagascar, 2020
PubMed ID: 41187342
Highly effective first‑line treatments for uncomplicated malaria improve individual recovery and public health.
Tissue repair (143)
- Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial
PubMed ID: 20877714
RDT‑guided CHW strategy that included AL and amoxicillin improved timely pneumonia treatment and reduced inappropriate antimalarial use — supports more appropriate recovery pathways.
- A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
PubMed ID: 19017387
Haemoglobin recovery reported but similar between arms—supports some recovery after parasite clearance.
- Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania
PubMed ID: 17996121
Haemoglobin recovery post-treatment suggests physiologic repair after malaria treatment.
- A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India
PubMed ID: 11037786
Rapid symptom and parasite clearance with high cure rate indicates accelerated recovery.
- Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children
PubMed ID: 9657512
Co‑artemether cleared parasites better and provided longer suppression of new infections vs chloroquine — aids convalescence and reduces relapse risk.
- Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria
PubMed ID: 9449273
Rapid resolution of illness with artemisinin combinations and higher cure for some regimens supports sustained recovery.
- Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial
PubMed ID: 33983371
Rapid parasite clearance and high day‑28 responses suggest quick clinical recuperation in asymptomatic patients.
- Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial
PubMed ID: 23113947
Pediatric trial: rapid parasite clearance and high efficacy — supports recovery from infection.
- Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study
PubMed ID: 24472156
Pediatric trial showing rapid parasite clearance and high cure rates — supports recovery.
- Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria
PubMed ID: 24468007
Documented early parasite clearance and factors that delay clearance; rapid clearance correlates with faster clinical recovery.
- Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria
PubMed ID: 24825870
Fewer hospital stays and reduced recurrence support faster clinical recovery and less morbidity.
- Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children
PubMed ID: 25436614
Repeated treatment over 2 years with rapid parasite and gametocyte clearance supports sustained clinical recovery.
- Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens
PubMed ID: 25652127
Rapid parasite clearance contributes to quicker symptom resolution though recurrences limited long-term recovery.
- Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial
PubMed ID: 26597254
Better hemoglobin recovery after ASAQ indicates improved physiological recovery post-infection.
- Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children
PubMed ID: 26502714
Documented anemia recovery kinetics after ACTs — relevant to convalescence and repair.
- [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]
PubMed ID: 26644184
ACTs were well tolerated and effective; clinical recovery outcomes reported at 28–42 days.
- In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014
PubMed ID: 27113085
Both ACTs improved hemoglobin by day 28 (~+1.2 g/dL), indicating recovery after infection.
- Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial
PubMed ID: 27649561
Haemoglobin recovery by Day42 after treatment suggests clinical recovery following malaria cure with ACTs.
- Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial
PubMed ID: 30668322
Faster fever and parasite clearance reported with Artemisia teas suggests quicker symptomatic recovery.
- Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial
PubMed ID: 30466622
Rapid elimination of schistosome eggs indicates faster recovery from helminth infection.
- Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria
PubMed ID: 1347854
Artesunate rapidly cleared parasites and, when followed by mefloquine, achieved complete cures—supports recovery and durable repair.
- Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria
PubMed ID: 1359318
Faster parasite clearance and higher cure rates with artemether imply more rapid recovery from infection.
- A comparative study of the schizontocidal efficacy and safety of artemether versus chloroquine in uncomplicated malaria
PubMed ID: 1477874
Markedly faster parasite clearance and far fewer recrudescences support quicker and more durable recovery.
- Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria
PubMed ID: 7886773
Rapid parasite clearance times and improved tolerability with artemisinin combinations → speeds clinical recovery.
- Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria
PubMed ID: 8024075
Artesunate+doxy cleared fever and parasites faster than comparator → accelerates symptomatic recovery though cure rate differed.
- Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria
PubMed ID: 8067808
Giving artesunate before mefloquine cleared parasites faster and increased cure rates → faster recovery and fewer relapses.
- Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination
PubMed ID: 7930743
Three-day artesunate+mefloquine dramatically reduced failure rates and sped symptomatic/parasitologic responses—supports faster recovery.
- Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria
PubMed ID: 8205643
Artesunate gave much faster parasite and fever clearance vs quinine+tetracycline → faster clinical recovery.
- Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria
PubMed ID: 8036679
Single-day artesunate addition prevented early failures and sped clinical/parasitological responses—helps recovery.
- Artemether-mefloquine combination in multidrug resistant falciparum malaria
PubMed ID: 7778152
Single-dose artemether produced rapid parasitemia clearance (most within 24h) and quick fever resolution → rapid recovery.
- Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine
PubMed ID: 8561267
Oral and IV artesunate provided similar rapid parasite/fever clearance → supports recovery regardless of route.
- Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria
PubMed ID: 8560531
Three-day artemisinin+mefloquine greatly reduced reinfection-adjusted failures and sped recovery—clinical recovery benefit.
- Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand
PubMed ID: 8594692
Intramuscular artemether significantly improved survival and cleared parasites faster than quinine in severe malaria—strong evidence for aiding recovery from severe infection.
- Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria
PubMed ID: 7485711
Faster fever and parasite clearance and higher cure rates support more rapid clinical recovery.
- Artemether or artesunate followed by mefloquine as a possible treatment for multidrug resistant falciparum malaria
PubMed ID: 8882193
Artemether or artesunate followed by mefloquine rapidly cleared parasites/fever and achieved high cure rates → rapid clinical recovery.
- Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients
PubMed ID: 8730315
Artesunate faster than artemisinin; autoinduction reduces drug exposure on repeated dosing but acute recovery is faster with artesunate.
- Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil
PubMed ID: 8619447
Artesunate+tetracycline cleared parasites much faster and had fewer side effects than quinine combinations → faster and better tolerated recovery.
- A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
PubMed ID: 8649493
Artemether cleared parasites faster and trended toward lower mortality vs quinine in severe malaria—supports recovery benefit.
- Open comparison of artemether and mefloquine in uncomplicated Plasmodium falciparum hyperparasitaemia in children
PubMed ID: 8787366
Faster parasite reduction and shorter clearance time → supports more rapid clinical recovery.
- An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children
PubMed ID: 8758084
Markedly faster parasite clearance though no mortality benefit overall → suggests quicker recovery from parasitemia.
- Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria
PubMed ID: 9231212
Faster parasite clearance and lower short-term mortality in some groups → supports faster clinical recovery in children.
- Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria
PubMed ID: 9196767
Improved cure and faster clearance when artemisinin added to mefloquine → promotes quicker resolution of illness.
- Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria
PubMed ID: 9230790
Longer artemether or sequential therapy gave higher cure rates and rapid symptom/parasite clearance → supports recovery.
- A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand
PubMed ID: 9561593
Short-course combinations led to high cure rates and rapid clearance → supports expedited recovery.
- A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand
PubMed ID: 9311648
Higher-dose artesunate produced faster parasite clearance and somewhat better 28-day cure → supports recovery.
- Two doses of artemether/mefloquine or artesunate/mefloquine combination for multidrug resistant falciparum Malaria
PubMed ID: 9656393
Two-dose regimens cured all patients and cleared fever/parasites within 48 h in most → strong recovery support.
- Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5- and 7-day regimens
PubMed ID: 9241384
5–7 day regimens resulted in near-universal cures and rapid parasite clearance → aids clinical recovery.
- [Comparison on treatment of falciparum malaria with different courses of artesunate tablet]
PubMed ID: 9863077
Longer courses greatly reduced recurrence, meaning more durable recovery/repair following therapy.
- Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria
PubMed ID: 9886194
Rapid parasite and fever clearance with low recurrence → supports prompt clinical recovery.
- Comparison of rectal artemisinin with intravenous quinine in the treatment of severe malaria in Ethiopia
PubMed ID: 10442116
Rectal artemisinin cleared parasites and fever faster with fewer side effects than quinine, supporting quicker recovery.
- Comparative efficacy of intramuscular artemether and intravenous quinine in Nigerian children with cerebral malaria
PubMed ID: 10546840
Artemether in cerebral malaria yielded rapid parasite and fever clearance, supporting clinical recovery.
- Efficacy and effectiveness of five day treatment of uncomplicated falciparum with artemisinin or artesunate in Vietnam
PubMed ID: 10695777
Supervised 5‑day regimens achieved 100% cure in efficacy settings—supports clinical recovery when adherence is ensured.
- Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics
PubMed ID: 10770766
Artemisinin combinations shortened parasite elimination half‑life vs quinine—facilitates faster recovery.
- A randomized controlled trial of artemotil (beta-arteether) in Zambian children with cerebral malaria
PubMed ID: 11220772
Intramuscular artemotil achieved outcomes similar to IV quinine for cerebral malaria, supporting comparable recovery.
- Rectal dihydroartemisinin versus intravenous quinine in the treatment of severe malaria: a randomised clinical trial
PubMed ID: 12858920
Rectal dihydroartemisinin cleared parasites faster and had fewer side effects than IV quinine → faster clinical recovery.
- Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria pregnant women
PubMed ID: 11800303
In pregnant women, artesunate+mefloquine cleared parasites and fever faster and preserved hematocrit better than quinine → improved recovery metrics.
- [A study of artemether combined with primaquine in the treatment of falciparum malaria]
PubMed ID: 12572052
Combination therapy (with primaquine) reduced relapses and maintained cure rates → supports sustained recovery and reduced recurrence.
- Artemether vs quinine therapy in Plasmodium falciparum malaria in Manipur--a preliminary report
PubMed ID: 12170942
Faster parasite clearance and fewer deaths with artemether vs quinine supports improved recovery outcomes.
- Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil
PubMed ID: 12471569
Artesunate sped clinical recovery (faster parasite and fever clearance) in large RCT—supports faster recovery from malaria.
- The efficacy of artemether versus quinine in the treatment of cerebral malaria
PubMed ID: 12214938
Cerebral malaria study: artemether produced slightly faster recovery times (fever, consciousness, parasite clearance) — relevant to recovery.
- [A randomized comparative study of naphtoquine, mefloquine and artsunate in the treatment of falciparum malaria]
PubMed ID: 14521743
Rapid fever and parasite clearance indicate faster clinical recovery though longer-term cure was lower vs comparator.
- A comparative clinical trial of artemether and quinine in children with severe malaria
PubMed ID: 14581730
Artemether led to faster coma recovery in children with severe malaria vs quinine.
- A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso
PubMed ID: 15078261
Faster fever and parasite clearance in children implies faster recovery from acute illness.
- Randomized control trial of quinine and artesunate in complicated malaria
PubMed ID: 15107507
Artesunate produced faster coma and fever resolution in complicated malaria — supports clinical recovery/repair after severe infection.
- Efficacy of mefloquine and mefloquine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon region of Bolivia
PubMed ID: 15040558
MQ+AS reduced gametocyte carriage and produced faster parasite decline—supports clinical recovery.
- Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial
PubMed ID: 15567011
Combos with artesunate greatly reduced treatment failures vs CQ+SP, reducing need for retreatment and improving recovery.
- Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola
PubMed ID: 15876443
Very low failure in children implies strong population-level recovery and reduced morbidity.
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
PubMed ID: 16125588
Mortality reduction and rapid parasite clearance in severe cases represent major recovery benefits.
- A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy
PubMed ID: 16088834
Fewer failures and faster clearance in pregnancy support maternal/infant recovery.
- A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria
PubMed ID: 16028147
High long-term cure rates support sustained recovery and reduced relapse-related morbidity.
- An open, randomized trial of three-day treatment with artesunate combined with a standard dose of mefloquine divided over either two or three days, for acute, uncomplicated falciparum malaria
PubMed ID: 16124422
Rapid clearance with near-perfect cure fosters effective recovery and repair.
- Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana
PubMed ID: 16054584
Artemisinin combos provided faster parasite/febrile recovery in children vs older drugs (accelerated convalescence).
- Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar
PubMed ID: 17519010
Faster parasite clearance and higher cure rates in pediatric malaria translate to more rapid clinical recovery.
- Artesunate, artemether or quinine in severe Plasmodium falciparum malaria?
PubMed ID: 17402835
Reduced mortality and faster parasite clearance in severe malaria directly indicate improved recovery outcomes.
- A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru
PubMed ID: 17971864
Faster parasite clearance at 24 h and fewer adverse effects support quicker symptomatic recovery.
- Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children
PubMed ID: 17325222
Artesunate regimens produced faster parasite clearance and reduced gametocyte carriage, supporting faster recovery.
- Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa
PubMed ID: 18154655
Dramatically lower treatment failure and faster fever/parasite clearance with AS+SP indicate improved convalescence and repair.
- Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria
PubMed ID: 17366451
Fewer recurrences and better hematologic recovery with DHP support improved recovery and repair after infection.
- Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria
PubMed ID: 17469728
Rectal artesunate produced effective parasite and fever clearance in children — useful for rapid initial treatment and recovery.
- Clinical efficacy of high dose monotherapy of oral dihydroartemisinin in uncomplicated falciparum malaria in viet nam
PubMed ID: 17642523
High-dose DHA produced fast parasite clearance but higher relapse rates; good for immediate parasite reduction but less durable recovery alone.
- Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
PubMed ID: 19059639
Pre‑referral artesunate halved death or permanent disability for delayed referrals—evidence it aids recovery and reduces long‑term harm from severe malaria.
- A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam
PubMed ID: 18337331
Artesunate relieved abdominal pain faster in fascioliasis patients — faster symptomatic recovery though lower 3‑month parasitological cure.
- Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children
PubMed ID: 18574653
Rapid parasite clearance with artesunate regimens shortens symptomatic period and aids clinical recovery.
- [Artesunate in interrupting the transmission of Plasmodium falciparum]
PubMed ID: 19157297
Rapid gametocyte clearance and elimination of mosquito infectivity can accelerate recovery and reduce onward transmission.
- Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial
PubMed ID: 19558654
Addition of artesunate to SP accelerated parasite clearance and improved Day42 cure—facilitates clinical recovery.
- Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
PubMed ID: 19698172
Pooled trials: rapid parasite clearance with artesunate combinations supports quicker recovery and reduced post‑treatment transmission.
- Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria
PubMed ID: 19505304
Fixed‑dose AS/AQ resulted in rapid parasitic and fever clearance (median parasite clearance ≈2 days), supporting faster recovery.
- Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy
PubMed ID: 19671190
Faster parasite clearance and lower gametocytaemia indicate quicker recovery and reduced onward transmission risk.
- Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali
PubMed ID: 19128455
Artemisinin combinations produced fastest parasite clearance and contributed to haemoglobin recovery in some arms (clinical recovery indicator).
- Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria
PubMed ID: 20398339
Artesunate led to faster parasite clearance and lower probability of coma—suggests improved recovery from severe malaria compared to artemether.
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
PubMed ID: 21062666
Parenteral artesunate reduced mortality and complications (hypoglycaemia, neurologic deterioration) versus quinine—strong evidence of aiding recovery in severe malaria.
- Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
PubMed ID: 21827706
Faster parasite clearance and high cure rates support clinical recovery, though direct measures of repair were not reported.
- Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial
PubMed ID: 21267072
Faster parasite clearance (median 23 h) indicates quicker clinical recovery from vivax malaria.
- Effects of lime juice on malaria parasite clearance
PubMed ID: 21413089
Adjunct lime juice accelerated parasite reduction time and higher proportion cleared by 72 h—preliminary evidence for faster recovery.
- Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa
PubMed ID: 21976561
Describes hematologic recovery after uncomplicated malaria; provides data relevant to clinical recovery timelines.
- Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial
PubMed ID: 22002979
DHP cleared parasites faster and reduced relapses, supporting sustained recovery and fewer recurrent episodes.
- A simplified intravenous artesunate regimen for severe malaria
PubMed ID: 22180622
Simplified 3‑dose IV artesunate regimen was non‑inferior for early parasite killing, supporting efficient early recovery in severe malaria.
- The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam
PubMed ID: 22741618
Artesunate–amodiaquine cleared parasites faster than comparator — supports quicker recovery.
- Current status of artemisinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in Bangladesh
PubMed ID: 23272227
Artesunate monotherapy led to rapid parasite clearance with patients aparasitaemic by 72 h, indicating prompt recovery.
- The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial
PubMed ID: 23175563
Shortened gametocyte carriage reduces onward transmission and may contribute to community-level recovery, but direct repair metrics not measured.
- Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial
PubMed ID: 22586253
Rapid parasite and fever clearance with arterolane+piperaquine supports clinical recovery after infection.
- Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana
PubMed ID: 23136273
Community antimalarial distribution reduced under‑five mortality, implying improved recovery and health outcomes.
- Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance
PubMed ID: 24354627
High cure rates and rapid clearance with ACTs aid clinical recovery in field settings.
- Efficacy of Quinine versus Artemether in the treatment of severe malaria
PubMed ID: 23787519
Artemether produced faster parasite clearance in severe pediatric malaria, facilitating recovery (although coma recovery differed).
- Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial
PubMed ID: 25093754
Reduced anemia and malaria incidence in children indicates improved recovery and resilience.
- Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial
PubMed ID: 24621953
IPT reduced malaria episodes and anemia in schoolchildren — contributes to improved recovery/resilience at population level.
- Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children
PubMed ID: 24943722
Adding artesunate improved parasite clearance and prevented day‑3 positivity — supports faster recovery from malaria.
- Comparison of artesunate and quinine in the treatment of severe Plasmodium falciparum malaria at Kassala hospital, Sudan
PubMed ID: 24820465
IV artesunate produced faster fever and parasite clearance in severe malaria, which accelerates clinical recovery.
- Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
PubMed ID: 26603174
Faster parasite clearance and reduced anemia risk with artesunate‑mefloquine vs chloroquine — supports clinical recovery and hematologic repair.
- Efficacy of a novel sublingual spray formulation of artemether in African children with Plasmodium falciparum malaria
PubMed ID: 26303805
Sublingual artemether cleared parasites much faster than IV quinine in children — rapid parasite clearance supports faster recovery.
- Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria
PubMed ID: 25801552
Sublingual artemether in children produced good exposures and rapid parasite clearance — supports effective recovery in pediatric patients.
- Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial
PubMed ID: 26757276
Simplified artesunate regimen achieved similar parasite reduction and may aid practical recovery/management in severe malaria.
- Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial
PubMed ID: 27107287
Artesunate‑mefloquine achieved faster parasite clearance and less anemia than chloroquine, aiding recovery.
- A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam
PubMed ID: 26856909
DHA‑PPQ produced faster parasite and fever clearance and fewer recurrences — supports quicker resolution and recovery.
- Economic evaluation of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital-Cameroon: a cost analysis
PubMed ID: 27923381
Artesunate shortened hospital stays and achieved faster parasite reduction vs quinine — supports faster clinical recovery.
- Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial
PubMed ID: 29281988
Artesunate produced faster parasite clearance in children with severe malaria, facilitating clinical recovery though reinfections occurred later.
- Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial
PubMed ID: 29538635
Acetaminophen reduced oxidative kidney injury and improved AKI outcomes in severe malaria — supports recovery of renal function.
- A Competing-Risk Approach for Modeling Length of Stay in Severe Malaria Patients in South-East Asia and the Implications for Planning of Hospital Services
PubMed ID: 29562258
Analysis showed artesunate reduced in‑hospital mortality and increased discharge probability—strong evidence of aiding recovery from severe malaria.
- Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial
PubMed ID: 31600221
MB+AS‑AQ accelerated parasite clearance—faster parasite removal can speed clinical recovery.
- Adherence to the referral advice after introduction of rectal artesunate for pre-referral treatment of severe malaria at the community level: a noninferiority trial in the Democratic Republic of the Congo
PubMed ID: 31864376
Pre‑referral rectal artesunate at community level used to stabilize children before referral—supports early treatment and recovery.
- Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine
PubMed ID: 31795967
Shows low partner‑drug levels increase recurrence risk — identifies exposure issues relevant to ensuring recovery.
- Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children
PubMed ID: 30418593
DHA‑piperaquine reduced recurrence vs AL — post‑treatment protection supports recovery and reduced relapse risk.
- The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR
PubMed ID: 31900172
Primaquine after DHA‑piperaquine prevented P. vivax relapses over 12 months — supports sustained recovery by preventing relapse.
- Malaria Chemoprevention in the Postdischarge Management of Severe Anemia
PubMed ID: 33264546
Monthly postdischarge DHA‑piperaquine cut readmissions and deaths through 26 weeks — robust evidence for aiding recovery after severe anemia.
- Imatinib augments standard malaria combination therapy without added toxicity
PubMed ID: 34436509
Imatinib added to DHA‑PPQ sped parasite and fever clearance, implying faster clinical recovery.
- Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa
PubMed ID: 33526485
Rectal artesunate initiates rapid parasite reduction in severe malaria, assisting early recovery while awaiting definitive care.
- Adherence to community versus facility-based delivery of monthly malaria chemoprevention with dihydroartemisinin-piperaquine for the post-discharge management of severe anemia in Malawian children: A cluster randomized trial
PubMed ID: 34506503
Post‑discharge monthly DP delivered in the community improved adherence and is linked to reduced readmissions and better recovery outcomes.
- Single-step versus conventional injectable artesunate for severe malaria in children: an open label, non-inferiority randomized clinical trial, Democratic Republic of the Congo and United Republic of Tanzania
PubMed ID: 41415126
One‑step artesunate provided equivalent parasite clearance with faster preparation—operationally supports prompt treatment and recovery.
- Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence
PubMed ID: 23945376
Residual submicroscopic parasitemia associated with higher recurrence — indicates slower or incomplete recovery when present.
- An open randomized controlled trial to compare the efficacy of two fixed dose combinations of artemesinin based combinations for uncomplicated falciparum malaria in Bangladesh
PubMed ID: 26118157
Rapid parasite and fever clearance with high cure rates supports clinical recovery from malaria.
- A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso
PubMed ID: 23442748
Screen‑and‑treat transiently improved Hb in asymptomatic carriers, which can support short‑term recovery of anemia‑related deficits.
- Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact
PubMed ID: 22764291
Repeated safe and efficacious ACT use over 24 months supports sustained treatment availability aiding recovery from recurrent infections.
- [A randomized clinical trial comparing the effectiveness and tolerability of artemisinine-naphthoquine (Arco®) and artemether-lumefantrine (Coartem®) in the treatment of uncomplicated malaria in Benin]
PubMed ID: 22328063
Faster parasite clearance with single‑dose artemisinin‑naphthoquine reduces illness duration.
- A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial
PubMed ID: 22087077
Large study showing consistent rapid clearance across sites—improves clinical recovery at scale.
- Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4-59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial
PubMed ID: 22172305
Monthly post-discharge AL reduced readmissions/deaths in children recovering from severe malarial anemia, indicating aid in recovery and prevention of relapse.
- Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia
PubMed ID: 21666744
AL associated with less early anemia and fewer treatment failures—promotes clinical recovery.
- Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance
PubMed ID: 21092220
Rapid cure in children though some had transient parasitaemia rises; overall supports faster recovery.
- Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan
PubMed ID: 20659392
Both combos led to rapid parasite and fever clearance and few side effects (supports recovery).
- The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso
PubMed ID: 20958888
Cleared parasites pre‑season but led to earlier reinfection; initial recovery benefit present though followed by more episodes.
- Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children
PubMed ID: 23349741
Rescue‑treatment trial reported mean hemoglobin increases and fewer recurrent infections with DHA‑piperaquine — evidence of clinical recovery.
- Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea
PubMed ID: 23403171
Rapid clinical and parasitological response to AL in young children, though vivax recurrences indicate need for radical cure — supports initial recovery.
- Efficacy of artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children
PubMed ID: 24334945
High cure rates and similar parasite/fever clearance times indicate effective recovery post‑treatment.
- [Efficacy and safety of antimalarial combinations for treatment of uncomplicated malaria in children in Bangui, Central African Republic]
PubMed ID: 24122669
High day‑28 ACPR and association of failures with resistance markers informs durable recovery prospects.
Immune support (27)
- HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria
PubMed ID: 16960779
Study shows HIV/immunosuppression (low CD4) increases recrudescence risk — links host immunity to treatment outcomes.
- Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia
PubMed ID: 21666744
AL produced fewer treatment failures and less early anemia vs comparator—beneficial hematologic/immune implications.
- Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anemia after treatment
PubMed ID: 20683244
ACTs associated with reduced anemia burden (AUC of hematocrit deficit) vs mefloquine, supporting blood/immune recovery.
- Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial
PubMed ID: 23468056
Trial showed tradeoffs in regimens (DP fewer reinfections but longer gametocyte carriage) relevant to immune/epidemiologic pressure.
- Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial
PubMed ID: 24239324
Single low‑dose primaquine added to AL markedly reduced gametocyte duration in children, which can help reduce onward infection pressure and indirectly support immune control.
- The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children
PubMed ID: 23382157
Large observational dataset showing different ACTs associate with differing gametocyte detection — relevant to population immune exposure.
- Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence
PubMed ID: 23945376
qPCR study linking residual parasitemia to greater infectivity and recurrence — clearing submicroscopic parasites supports host control of infection.
- Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children
PubMed ID: 25246693
Large trial showing rapid parasite and fever clearance with ACTs and reduced gametocyte carriage, lowering infectious burden on host immunity.
- Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial
PubMed ID: 25414262
Adding ivermectin to AL increased mosquito mortality and reduced transmission potential, indirectly reducing infectious challenge to immunity.
- Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
PubMed ID: 28216244
PfSPZ whole‑sporozoite vaccine produced antibody responses and partial protection against P. falciparum — direct evidence of inducing protective immunity.
- Preventive effect of artemether on schistosome infection
PubMed ID: 10374370
Preventing schistosomiasis exposure reduces infection burden and acute disease, indirectly supporting community immune health and disease prevention.
- Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial
PubMed ID: 19098989
Monthly AS+AQ IPTc reduced clinical malaria and anaemia risk in children — indirect support for improved host health/hematologic status.
- Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya
PubMed ID: 19194499
ACTs including artesunate markedly reduced submicroscopic gametocyte burden and mosquito infections, indicating strong antiparasitic/immunity‑relevant effects.
- Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana
PubMed ID: 23136273
Reduced under‑5 mortality with community antimalarial delivery implies improved population resilience to infection.
- Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance
PubMed ID: 24354627
High field effectiveness of ACTs reduces infection pressure and may support population health/immune status.
- Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10
PubMed ID: 27067196
Monthly DP reduced malaria and was linked to more protective CD4+ T‑cell phenotypes (direct immunologic evidence).
- Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers
PubMed ID: 31306084
RTS,S vaccine immunogenicity not reduced when given with DP±primaquine—relevant to vaccine/antimalarial immune interactions.
- Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women
PubMed ID: 31133672
Pregnancy study showing similar malaria antibody measures across interventions—relevant to humoral immunity in treated populations.
- Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
PubMed ID: 31075171
Direct human data: pre‑existing antibody functions (IgG3, complement, opsonic phagocytosis) materially sped artesunate parasite clearance — strong link to immune mechanisms.
- Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial
PubMed ID: 33891721
Monthly DP in pregnancy reduced placental malaria and low birth weight — indirect immune/host‑protection benefit in pregnancy.
- Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
PubMed ID: 36451216
Therapeutic efficacy trials show rapid parasite clearance with ACTs — direct reduction of infectious challenge relevant to immune health.
- Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial
PubMed ID: 38224706
Monthly DP in pregnant women reduced clinical malaria, indirectly supporting maternal immune outcomes.
- Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial
PubMed ID: 38224710
Adding DP to co‑trimoxazole in pregnant women with HIV lowered malaria infections (immune‑relevant outcome).
- The effects of Annual SZ drug on dynamic changes in lymphocytes and cytokines of COVID-19 patients: A randomized clinical trial
PubMed ID: 38237225
Small randomized trial of an artemisinin syrup in COVID‑19 reported increased T‑cell counts and lower IL‑6 — direct immune marker changes.
- Dihydroartemisinin-piperaquine effectiveness for seasonal malaria chemoprevention in settings with extended seasonal malaria transmission in Tanzania
PubMed ID: 38273019
SMC with DHA‑PPQ associated with lower malaria prevalence and less anemia—indirect support for immune/hematologic health.
- Targeting malaria in high-risk populations in low endemic regions in northern Namibia: a quasi-experimental controlled trial to reduce malaria in seasonal agricultural workers and cattle herders
PubMed ID: 39961693
Worksite interventions reduced malaria prevalence and showed some anemia decline, supporting community health.
- Effectiveness of sulfadoxine-pyrimethamine plus amodiaquine and dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial
PubMed ID: 39826559
SMC trials showed large reductions in malaria and anemia in children, improving host resilience and immune‑related outcomes.
Cell health (18)
- Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial
PubMed ID: 26429700
DHA‑PQP IPT in pregnancy reduced maternal anaemia and placental malaria — preserves maternal/placental cellular health.
- [Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]
PubMed ID: 18241646
In advanced NSCLC adding artesunate to vinorelbine–cisplatin increased disease control rate though no overall survival benefit at one year — suggests possible adjunct anticancer activity.
- Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria
PubMed ID: 17366451
DHA–piperaquine produced better hematological recovery and fewer recurrent infections than artesunate–amodiaquine, indicating improved blood/cellular recovery post-infection.
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
PubMed ID: 16125588
Mortality reduction and rapid parasite clearance in severe malaria reflect major restoration of critical cellular/organ function.
- In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014
PubMed ID: 27113085
Therapeutic study reported haemoglobin recovery after ACT treatment in toddlers.
- Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children
PubMed ID: 26502714
Detailed haematocrit kinetics after ACTs documented anemia recovery dynamics and rare late falls.
- Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial
PubMed ID: 26597254
ASAQ led to better hemoglobin recovery than AL — direct cellular/hematologic recovery evidence.
- Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia
PubMed ID: 21666744
Less and shorter post‑treatment anemia with artesunate combos vs comparator suggests cellular/hematologic benefit.
- Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
PubMed ID: 29764419
No instances of ALT/AST >3×ULN observed with pyronaridine–artesunate, indicating preserved liver biomarker status.
- Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
PubMed ID: 26601738
Re-treatment with pyronaridine‑artesunate did not increase liver safety risks (ALT/AST/bilirubin), supporting hepatocellular safety.
- Plasma folate dynamics in Plasmodium falciparum-infected African children treated with artemisinin combination therapy and single low-dose primaquine or placebo
PubMed ID: 41094485
Serial plasma folate measurements around malaria treatment document transient folate changes—relates to cellular nutrition/homeostasis.
- Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
PubMed ID: 31075171
Shows antibody‑mediated functions (IgG3, opsonic phagocytosis, complement) accelerate parasite clearance — direct cellular immune relevance.
- Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial
PubMed ID: 29538635
Shows reduction in oxidative kidney injury markers and better renal outcomes — supports cellular/tissue protection in severe malaria.
- Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial
PubMed ID: 28108368
SP+PQ IPT in schoolchildren reduced anaemia and improved hemoglobin over 12 months—direct cellular/hematologic benefit.
- Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial
PubMed ID: 27107287
Artesunate‑mefloquine led to less anemia at day 28 compared with chloroquine—supports hematologic/cellular health.
- Malaria illness mediated by anaemia lessens cognitive development in younger Ugandan children
PubMed ID: 27076184
Chemoprevention reduced malaria and anemia in young children; anemia mediation linked to developmental outcomes—cellular health implication.
- Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy
PubMed ID: 26962728
Monthly DP in pregnancy markedly reduced placental malaria and parasitemia — supports placental/cellular health.
- Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
PubMed ID: 26603174
Artesunate‑mefloquine reduced anemia risk in P. knowlesi patients vs chloroquine — benefits to hematologic/cellular status.
Energy & Fatigue (6)
- Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial
PubMed ID: 30865632
SMC increased mean hemoglobin (+5.9 g/L), which can improve energy/fatigue in children.
- Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children
PubMed ID: 20689585
Large Ugandan cohort documented marked declines in malaria and anemia over 4 years with ACTs in programmatic use — reduced anemia plausibly links to improved energy.
- Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial
PubMed ID: 22166001
Cluster RCT of seasonal preventive antimalarials showed reduced anemia in children (41% protective efficacy), which can translate to better energy.
- A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso
PubMed ID: 23442748
Community screen-and-treat with AL produced a short-term mean Hb increase (+0.53 g/dL) in asymptomatic carriers, a plausible mechanism for improved energy.
- Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali
PubMed ID: 19497079
Preventive artesunate combos in schoolchildren reduced clinical malaria and raised mean haemoglobin (~+0.6 g/dL), which could plausibly improve energy/fatigue.
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
PubMed ID: 16125588
Mortality reduction and faster clearance in severe malaria dramatically improve clinical recovery and likely energy in survivors.
Inflammation (9)
- Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast
PubMed ID: 20214761
Rapid fever clearance in both artesunate‑containing regimens implies reduced inflammatory response.
- The effects of Annual SZ drug on dynamic changes in lymphocytes and cytokines of COVID-19 patients: A randomized clinical trial
PubMed ID: 38237225
Reported significant IL‑6 reduction in a small randomized COVID‑19 trial with an artemisinin syrup — direct anti‑inflammatory signal.
- Efficacy and safety of artemether emulsion for the treatment of mild-to-moderate acne vulgaris: a randomized pilot study
PubMed ID: 31884836
Topical artemether reduced acne lesions and severity, effects that likely reflect reduced local inflammation.
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
PubMed ID: 16125588
Mortality reduction and rapid parasite clearance in severe malaria imply major reduction in infection-driven inflammatory morbidity.
- Randomized control trial of quinine and artesunate in complicated malaria
PubMed ID: 15107507
Faster clinical recovery (coma/fever) in severe malaria suggests reduced pathologic inflammatory burden, though inflammation markers were not directly measured.
- A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso
PubMed ID: 15078261
Faster fever and parasite clearance with artesunate suggests faster resolution of inflammatory symptoms.
- Intramuscular artemether vs intravenous quinine: an open, randomized trial in Malawian children with cerebral malaria
PubMed ID: 9484961
Artemether produced faster fever resolution (fever being an inflammatory symptom), implying reduced inflammatory burden.
- Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria
PubMed ID: 9546416
High‑dose pentoxifylline during artesunate therapy reduced TNF and IL‑6 significantly — shows inflammatory modulation during artemisinin treatment (adjunct effect).
- Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan
PubMed ID: 20659392
Rapid fever/parasite clearance in both artemisinin combo arms indicates inflammation reduction.
Mental clarity (2)
- Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria
PubMed ID: 1287904
Artemisinin suppositories cleared parasites much faster and trends toward faster coma recovery vs quinine (clinical improvement in mental status).
- The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii
PubMed ID: 24656425
Double‑blind adjunctive artemether in Toxoplasma‑seropositive schizophrenia modestly improved negative symptoms and global scores (cognitive/clinical domains).
Detoxification (2)
- Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects
PubMed ID: 17521300
Demonstrated induction of major hepatic CYPs (CYP3A, CYP2C19) by artemisinin—directly relevant to metabolic detoxification.
- Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania
PubMed ID: 20713675
Population PK data on artemether/DHA and lumefantrine metabolism inform hepatic processing and clearance.
Skin health (2)
- Efficacy and safety of artemether emulsion for the treatment of mild-to-moderate acne vulgaris: a randomized pilot study
PubMed ID: 31884836
Randomized pilot: topical artemether significantly reduced acne severity and lesion counts versus comparator over 12 weeks.
- Evaluation of the efficacy and safety of artemether emulsion on localized senile pruritus: A randomized pilot study
PubMed ID: 36107571
Randomized pilot: 1% artemether cream markedly reduced itch in senile pruritus vs emulsion — direct, high-relevance skin benefit.
Digestive support (1)
- Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial
PubMed ID: 32966290
Adding dihydroartemisinin–piperaquine to praziquantel increased cure rates and egg reduction for intestinal schistosomiasis — benefit for intestinal/parasitic burden.
Heart health (1)
- Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate
PubMed ID: 16103586
Small randomized study found adding artesunate to atovaquone-proguanil did not prolong QTc, supporting cardiac safety (moderate evidence).
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Artemisinin
Search all65 products whose verified label declares Artemisinin — not every bottle that mentions it in a title.